

The missing link between autoimmune diseases and microchimerism

Kenji Hayashida

Second Department of Internal Medicine, Nagasaki University School of Medicine, Nagasaki.
852-8501, Japan, khayashida1952@yahoo.co.jp

Keywords: autoimmune disease, chronic graft-versus-host disease, microchimerism, gender bias, bone marrow transplantation, long-lived memory plasma cell, mesenchymal stem cell, H-Y antigen, anti-sperm antibody, mitophagy, exosome, SPAG1, Eri15, X-linked microRNA

ABSTRACT

Background

Autoimmune diseases (AIDs) are characterized by being more common in females, but the cause is still unclear. Among the hypotheses explaining the reason, fetal microchimerism (Mc) involvement theory is the most convincing, but it is unclear how Mc cells impair recipients, and there is a significant missing link. The incidence of chronic graft-versus-host disease (cGVHD) after bone marrow transplantation (BMT) or hematopoietic stem cell transplantation (HSCT), which is the basis of the Mc theory of AIDs, also has a gender bias due to the combination of donor and recipient, but the cause is unknown. It is assumed that bone marrow cells (BMC) attacking allogeneic somatic cells (Soc) is the common cause of cGVHD and AIDs, and the encounter probability between both is correlated with the incidence of cGVHD and AIDs, and combining both genders gives gender bias. It is thought that examining which combination matches the actual gender bias and incidence of cGVHD and AIDs will validate the Mc etiology theory of AIDs.

Methods

The onset probability (OnP) is the sum of the encounter probabilities (EnP) of all combinations of BMC and allogeneic Soc caused by Mc. EnP is expressed as the product of the existence probability (ExP) of BMC and allogeneic Soc. ExP is expressed as the product of probabilities by factors such as the Mc pathway and cell aging involved in the existence of each cell. OnP was calculated for each gender combination of BMC and Soc to verify whether it matched the actual gender bias and incidence of cGVHD and AIDs.

Results

The combination of female BMC attacking male Soc, a unidirectional heterosexual relationship, best matched the actual gender bias and incidence of cGVHD and AIDs.

Conclusions

The author hypothesized that the cause of AIDs is the same as cGVHD after BMT, and encounters between BMC and Soc in an allogeneic relationship brought about by Mc determine gender bias and incidence and simulated the encounter probability for each gender combination. As a result, it was found that assuming that female BMC attacks male Soc can best explain the gender bias and incidence of cGVHD and AIDs. Furthermore, it is speculated that the target factor is H-Y antigen and the effector cell is H-Y antigen-specific long-lived memory plasma cell, and the author considered the missing link between AIDs and Mc.

INTRODUCTION

Since Hashimoto reported chronic thyroiditis (Hashimoto's disease) in 1912,¹ many AIDs have been discovered. The estimated prevalence of overall AIDs is 4.5% worldwide.² They form a large and diverse group of diseases, ranging from AIDs that cannot be questioned by anyone (so-called classic AIDs) to those with unclear autoimmune reactions (chronic inflammatory syndromes).³ It is no exaggeration to say that the quest to elucidate the etiology of AIDs has driven the development of immunology. However, many etiological hypotheses have been proposed for 110 years since the discovery of Hashimoto's disease, but there is still no definitive one. There are three common phenotypes of classical AIDs: (1) Chronic inflammatory disease. (2) Tissue damage caused by autoreactive molecules (autoantibodies) or cells (autoreactive T cells). (3) It is overwhelmingly common in adult females. Chronic inflammation is fundamental and essential to the pathogenesis of AIDs. Autoantibodies are a characteristic finding that constitutes a means for diagnosing AIDs, and AIDs can be divided into the following four types from the standpoint of autoantibodies: 1) AIDs with pathogenic autoantibodies. 2) AIDs with only nonpathogenic autoantibodies. 3) AIDs without autoantibodies. 4) Special type with autoantibodies but no AIDs. Gender bias, which is more

prevalent in adult females, is also a prominent feature of AIDs, and at least the etiological hypothesis that fails to explain the overwhelming female dominance seen in classic AIDs is incomplete, which means that something is missing or wrong. However, some cases of AIDs have no gender bias in young people or are slightly more prominent in males (Fig. 1). It should be verified whether the AIDs etiological hypothesis can include not only typical cases but also exceptional diseases.

As hypotheses to explain this gender bias, there are sex hormone or sex chromosome involvement theory. However, it is difficult to explain for AIDs, which is common in young people. There is a report that the presence or absence of pregnancy history was the only influence on the onset in multivariate analysis in primary biliary cirrhosis with a female-to-male ratio of 9:1.⁴ Approximately 8% of females after pregnancy develop postpartum autoimmune thyroiditis.⁵ These findings suggest that pregnancy is intensely involved in developing female-dominant AIDs. Nelson et al. focused on natural microchimerism (Mc) as an etiology of systemic sclerosis (SSc) because of the similar phenotypes of SSc and chronic graft-versus-host-disease (cGVHD) after BMT.⁶ Mc is the state in which another individual's cells are mixed in small amounts. Mammals exchange each other's cells between the mother and the fetus through the placenta. In the case of stem cells, they can be established over several decades.⁷ It is not a rare occurrence, but it happens frequently and can be said to be the fate of mammals. The Mc caused by pregnancy is called natural Mc, while that caused by medical procedures such as blood transfusion and organ transplantation is called artificial Mc.⁸ Male cells were detected in 59% of SSc females in the blood (25% in controls).⁶ Since then, fetal-derived Mc (FMc) cells and mother-derived Mc (MMc) cells have been detected with various AIDs.⁹ Nelson et al. suggest that the involvement of Mc in AIDs may be due to the relationship of human leukocyte antigen (HLA) between Mc and the host. However, there is no clear explanation for the mechanisms underlying AIDs development and the female predominance etc., indicating the presence of a missing link between AIDs and Mc. The author speculated that the Mc hypothesis has the highest possibility of explaining the female predominance among the many AIDs etiology theories and that the gender of Mc cells and host cells, which are in an allogeneic relationship, determines the gender bias of AIDs.


Even in cGVHD, which is said to be the phenocopy of AIDs,¹⁰ there is a gender bias that the combination of female donor and male recipient (F→M) has the highest incidence rate of cGVHD. At first glance, the female BMC seems to be attacking the male Soc, but it also develops in other combinations.¹¹⁻¹³ After BMT, various AIDs develop, and cGVHD may be a type of AIDs rather than a phenocopy of AIDs. If AIDs and cGVHD consider Mc as a common etiology, the cell clusters brought in by BMT may also cause AIDs. Although the cell types transferred by natural Mc are diverse, BMT, which destroys the recipient's bone marrow during pretreatment, has few factors involved and is very suitable for pathogenesis analysis among artificial Mc. Potential target cells for artificial Mc would be organ somatic cells or tissue-specific stem cells. If the tissue-specific stem cells are target cells, the tissue can not be repaired, and the tissue seems to be depleted. However, no such observation has been reported, so the target cells are probably the recipient somatic cells. Possible effector cells in BM administered with BMT include cytokines, mature blood cells, long-lived memory T and B cells, hematopoietic stem cells (HSC), and stromal cells (such as mesenchymal stem cells (MSC) and fibroblasts).^{14,15} Since cGVHD and AIDs are chronic inflammatory diseases, short-lived cytokines and mature blood cells cannot be considered as effector cells. Therefore, the factors involved in the pathogenesis of cGVHD may be somatic cells (Soc) as target cells, long-lived bone marrow cells (LLBMC) (long-lived memory T and B cells, HSC, MSC and fibroblasts) and mature blood cells differentiated from HSC as effector cells. The cell types considered for the cause of AIDs and cGVHD can be simplified to two allogeneic-related LLBMC and Soc. It is highly likely that the gender combination of LLBMC and Soc causes gender bias in AIDs and cGVHD. Therefore, it can be inferred that the encounter probability of allogeneic LLBMC versus Soc correlates with disease incidence and gender bias.

Mc cells have been detected at damaged sites of maternal tissue and are thought to play an active role in tissue repair.¹⁶ It has been reported that Soc is replaced by Mc cells in damaged organs of AIDs.⁹ The recipient Soc is thought to contain Mc-derived maternal and sibling cells. Among LLBMC, it is MSC that can repair tissue. Therefore, it is necessary to consider not only recipient Soc but also chimeric Soc as target cells. When the target cells are recipient Soc, the relative number of recipient Soc to the effector factor is much larger than the chimeric Soc replaced by MSC, so the effect is thought to be diluted and attenuated, and it is necessary to consider the dilution effect. In natural Mc, not only between mother and fetus but also the stem cells of the older brother and sister may be transmitted to the younger brother and sister through the mother's body. In the case of multiple births, the influx occurs in the uterus via the placenta as well as via the mother (this route cannot be ignored in laboratory animals where multiple births are the basis). In addition, the stem cells of grandmother, uncle, and aunt will also be transmitted to the fetus through the mother. However, LLBMC are not totipotent stem cells and have a lifespan, so the chain of Mc effects through the pregnant females will not last long. Since the onset of AIDs is rare in people over the age of 80 years old,² it is thought that LLBMC has a healthy lifespan,¹⁷ and its activity and

number as effector factors decline with aging. Therefore, it is necessary to consider the difference in the effect of receiving aged maternal LLBMC or young fetal LLBMC.

From the above, in the all gender combination of LLBMC and Soc that have an allogeneic relationship, the product of the existence probability (ExP) of each cell is the encounter probability (EnP), and the sum of EnP is the onset probability (OnP) and examined which combination could explain the gender bias and incidence of AIDs and cGVHD. As a result, it turned out that assuming that female LLBMC is attacking male Soc can explain almost of the gender bias and incidence of AIDs and cGVHD. This time, a part of the missing link between Mc and AIDs was clarified in this study, but the effector cell or factor of female LLBMC and the target factor of male Soc remain unknown. The author would like to discuss the possible molecules and mechanisms and present hypothesis.

Figure 1. Distribution of autoimmune diseases by onset age and female/male ratio. Red circle: autoantibodies (+)/pathogenic molecular target (+). Orange circle: autoantibodies (+)/pathogenic molecular target (-), Green circle: autoantibodies (-)/pathogenic molecular target (-). Small circle: 0.1~10 prevalence per 10^5 people. Medium circle: 10~100 prevalence per 10^5 people. Large circle: >100 prevalence per 10^5 people. AIDs with a prevalence of less than 0.1 were excluded. Blue character: IgG4-RD. Referring to Hayter et al. 2012, added the following: IgG4-RD (AIP, PSC, RT, MD, TIN),¹⁹⁷⁻²⁰¹ AS,²⁰² PSV/PSP,²⁰³ ASD,²⁰⁴ DCM,²⁰⁵ PMR,²⁰⁶ MGN,²⁰⁷ OLP²⁰⁸ and IgAN²⁰⁹. (See Supplementary information for AIDs abbreviations.)



METHODS

Allogeneic relationship of effector/target cells

The following six combinations of effector/target gender can be considered for LLBMC and Soc in the allogeneic relationship: (1) female LLBMC is attacking male Soc ($\text{♀} \rightarrow \text{♂}$). (2) Male LLBMC is attacking female Soc ($\text{♂} \rightarrow \text{♀}$). (3) Both sexes are attacking in both directions ($\text{♀} \rightleftharpoons \text{♂}$). (4) Attacking between female ($\text{♀} \rightarrow \text{♀}$). (5) Attacking between male ($\text{♂} \rightarrow \text{♂}$). (6) LLBMC is attacking all of allogeneic Soc regardless of gender (all LLBMC \rightarrow all Soc).

Existence probability (ExP) of each cell

Five parameters and coefficients are considered for natural Mc and six for artificial Mc as factors that determine the existence of each cell, and the product is ExP (Fig. 2, 3). The range of influential Mc is up to the mother, older siblings, and children; the grandmother's Mc was excluded as they were considered advanced in age. The ExP of the self LLBMC is set to 1.0, the ExP of chimeric LLBMC transferred and established between mother and child is set to 0.1, and the ExP of chimeric LLBMC received from older sibling via mother is 0.1x0.1 (Mc parameter). For both natural Mc and artificial Mc, it is assumed that adult females become pregnant at 30 years old, with one male and one female, and there are no pregnancies under 20 years old. The probability of pregnancy of adult females who have experienced pregnancy is 1.0, and the probability of pregnancy of individual adult females is assumed to be 0.5 (pregnancy coefficient). The probability of having a mother is 1.0, and the probability of having older siblings is assumed to be 0.5 (sibling coefficient). If there are siblings, there is one older brother and one older sister (there is no age difference between them), and the age difference between the older siblings and the subject is two years, and cases of multiple births are not included. The dilution effect due to diffusion is 1.0 when the target is chimeric Soc and 0.1 when the target is recipient Soc (dilution coefficient). Since the onset age of AIDs is up to the 60s, and there are few in the 70s to 80s,² the healthy lifespan of stem cells, including MSC, is 80 years old. The functional decline (reduction of number) is 1/80 per year, and the LLBMC activity is expressed as $1 - \text{age}/80$ (1.0 at 0 years old and 0 at 80 years old) (aging parameter). The target age for natural Mc is from 10 to 80 years old. For artificial Mc, both donor and recipient are 30 years old. Since the artificial Mc by sibling-sibling and parent-child BMT causes a combination of syngeneic relationships between chimeric cells, the ExP of allogeneic cells between chimeric cells of different ages is 1.0, and the ExP between the same age is 0.5 (syngeneic

coefficient).

Encounter probability (EnP)

The product of ExP between each cell is EnP, and the sum of EnP between all cells is the OnP of the individual. In six combinations of effector/target cells, natural Mc simulates OnP for each gender and age, and artificial Mc simulates OnP for each gender combination of donor and recipient. In natural Mc, an example of a 30-year-old female with female effector/male target (♀→♂) is shown in Fig. 2. In artificial Mc, an example of female effector/female target (♀→♀) and male donor/female recipient (M→F) is shown in Fig. 3.

Matching phenotypes

The following six characteristics of AIDs and cGVHD to be collated were verified: 1) In adult AIDs, many female-dominant diseases are highly prevalent. 2) There is also AIDs, which is more common in middle-aged and elderly males, but the prevalence is low. 3) In young AIDs, diseases with a female/male ratio of 1 or less are predominant, and there are a few diseases with a slightly higher female ratio (Fig. 1). 4) The incidence of cGVHD is highest in gender mismatch from female donor to male recipient (F→M). 5) cGVHD also develops in other combinations.^{12,13,18} 6) The risk of developing cGVHD according to the donor's pregnancy history is significantly higher for parous females than for male donors. It tends to be lower for nulliparous females than parous females, but the difference is insignificant.¹⁹ (There is also a report that it is as low in nulliparous females as in male donors.²⁰)

Figure 2. Natural microchimerism: simulation of onset probability. OnP: onset probability. EnP: encounter probability. ExP: existence probability. M: Mc parameter. S: sibling coefficient. P: pregnancy coefficient. A: aging parameter. D: dilution coefficient. LLBMC: long-lived bone marrow cells. Soc: somatic cells. Circle: LLBMC (effector). Square: somatic cells (target). Orange circle (square): own cells. Red circle (square): maternal Mc cells. Green circle (square): sibling Mc cells. Blue circle (square): fetal Mc cells. Number in the circle (square): age of cells. Circle (square) with +: female cells. Circle (square) with arrow: male cells. Example is a case of a female effector/male target combination (♀→♂) in a 30-year-old female.





Figure 3. Artificial microchimerism: simulation of onset probability. OnP: onset probability. EnP: encounter probability. ExP: existence probability. M: Mc parameter. S: sibling coefficient. P: pregnancy coefficient. A: aging parameter. D: dilution coefficient. Sy: syngeneic coefficient. LLBMC: long-lived bone marrow cells. Soc: somatic cells. Circle: LLBMC (effector). Square: somatic cells (target). Orange circle (square): own cells. Red circle (square): maternal Mc cells. Green circle (square): sibling Mc cells. Blue circle (square): fetal Mc cells. Number in the circle (square): age of cells. Circle (square) with+: female cells. Circle (square) with arrow: male cells. Example is a case of a female effector/female target combination (♀→♀) in a male donor/female recipient (M→F).




RESULTS

Natural Mc

The incidence frequency of natural Mc in all combinations, males gradually decreased from 10 years old to peak with age to 0 at 80 years old, and females decreased from 10 to 20 years old, then increased at the age of 30 at the age of pregnancy and then decreased gradually. The aging changes in females were consistent with the observation that AIDs increases after pregnancy. The male-to-female ratio in youth was slightly male-dominant in $\text{♀} \rightarrow \text{♂}$, and strongly male-dominant in $\text{♂} \rightarrow \text{♀}$ and $\text{♀} \rightarrow \text{♀}$, and the same frequency in all LLBMC \rightarrow all Soc. In adults, female predominance was strong in $\text{♀} \rightarrow \text{♂}$ and $\text{♀} \rightarrow \text{♀}$, and mild female predominant in $\text{♀} \rightarrow \text{♂}$ and all LLBMC \rightarrow all Soc (Fig. 4, Table S1, S2). Only $\text{♂} \rightarrow \text{♂}$ became dominant in middle-aged and elderly males, but they were male-dominated at all ages (Fig. 4E). From the above, in natural Mc, $\text{♀} \rightarrow \text{♂}$ best matched the gender bias of AIDs, followed by all LLBMC \rightarrow all Soc. However, no combination could explain all the phenotypes, including the middle-aged and elderly male-dominated AIDs.

Figure 4. Natural microchimerism: Odds of onset probability by gender and age for each combination of effector cells/target cells. A: female effector \rightarrow male target ($\text{♀} \rightarrow \text{♂}$). B: male effector \rightarrow female target ($\text{♂} \rightarrow \text{♀}$). C: female effector and target = male effector and target ($\text{♀} \rightarrow \text{♂}$). D: female effector \rightarrow female target ($\text{♀} \rightarrow \text{♀}$). E: male effector \rightarrow male target ($\text{♂} \rightarrow \text{♂}$). F: all LLBMC effector \rightarrow all allogeneic Soc target (allLLBMC \rightarrow allSoc). Red line: female. Blue line: male.




Artificial Mc

Only $\text{♀} \rightarrow \text{♂}$ matched the observation that the onset of cGVHD is highest in the case of F \rightarrow M (Fig. 5A, Table S3). In addition, $\text{♀} \rightarrow \text{♂}$ and $\text{♀} \rightarrow \text{♀}$ matched the observation that the incidence of cGVHD of parous donors tended to be higher than that of nulliparous donors and significantly higher than that of male donors (Fig. 5B, Tables S4, S5).

There was no significant difference in natural Mc and artificial Mc results if each probability coefficient and parameter was $0 \leq p \leq 1.0$. From the above, the simulation of $\text{♀} \rightarrow \text{♂}$ between unidirectional heterosexuals best matched the actual gender bias and incidence of AIDs and cGVHD. That is, it is considered that the female LLBMC is attacking the male somatic cell.

Figure 5. Artificial microchimerism: A: Odds of onset probability by gender of donor and recipient for each combination of effector cells/target cells. Orange bar: female donor/male recipient (F \rightarrow M). Yellow bar: female donor/female recipient (F \rightarrow F). Green bar: male donor/male recipient (M \rightarrow M). Blue bar: male donor/female recipient (M \rightarrow F). B: Odds of onset probability by pregnancy history of the donor for each combination of effector cells/target cells. Red bar: parous donor \rightarrow all recipients (F** \rightarrow X). Cream bar: nulliparous donor \rightarrow all recipients (F* \rightarrow X). Pale blue bar: male donor \rightarrow all recipients (M \rightarrow X).



DISCUSSION

Gender bias

AID and GVHD When AIDs is divided into four regions based on gender (female/male ratio=1.0) and onset age (20 years old), it can be seen that it is distributed into the following three groups (Fig. 1): Group 1: This group overwhelmingly affects young adults to middle-aged females, has a high prevalence rate, and is the group to which the most research and medical resources have been devoted, and it can be said that it is a classic AIDs. Group 2: In young people, diseases with a female/male ratio of 1 or less are the main. There are a few diseases with a slightly more female but no apparent female-dominant disease like group 1. This group has no low prevalence, including Coeliac disease and type 1 DM. Group 3: There is a group of middle-aged to older adults, clearly more prevalent in males but with a lower prevalence. Group 3 AIDs include IgG4-related disease (IgG4-RD), which has recently attracted attention.²¹

In cGVHD, the combination of female donor and male recipient has the highest incidence rate, but other combinations also develop.¹¹⁻¹³ In addition, the risk of cGVHD was high in the case of older female donors^{22,23} and parous donors^{19,20}. Both AIDs and cGVHD strongly suggest that pregnancy is involved in the onset. GVHD that occurs within 100 days after BMT was classified as acute GVHD (aGVHD), and what occurs after that is cGVHD, but recently it has been classified by phenotype. It is because there are aGVHD that occurs even after 100 days and cGVHD that occurs even within 100 days. aGVHD develops in 35~50% of patients after HSCT,²⁴ primarily affecting the skin, gastrointestinal tract, and liver, and lesions with a strong inflammatory component, according to a Th1/Th17-driven process. Since aGVHD can be prevented by transplantation of T cell-depleted grafts, donor cytotoxic T cell is the main cause.²⁵ The lifespan of lymphocytes is about two weeks,²⁶ and it is thought that donor mature T cells or donor HSC-derived T cells are involved. Recently, it has been found that there is an overlap syndrome in which cGVHD and aGVHD co-occur.²⁷ In BMT, in which the recipient HSCs are depleted by pretreatment, the lymphocytes responsible for aGVHD and cGVHD are derived from the same donor, and it is unlikely that the same cells exhibit different phenotypes simultaneously. Therefore, the primary etiology, particularly effector cells, of aGVHD and cGVHD are considered to be different. cGVHD develops in 30-70% of patients after HSCT²⁸ and damages a broader range of organs, mainly on the same skin, gastrointestinal tract, and liver as aGVHD. The lesions exhibit autoimmune and fibrotic features.²⁵ 50% of patients who were able to prolong life after the onset of aGVHD develop cGVHD, and most cGVHD has aGVHD as a precursor, so aGVHD is considered to be the risk factor of cGVHD.²⁴ cGVHD is not preventable by T cell-depleting therapy²⁹ and is a Th2-dominant reaction in which B cell dysregulation results in the emergence of autoreactive B cells and autoantibody production.^{25,30} Antinuclear and anti-dsDNA antibodies appear in more than 50% of cGVHD, so cGVHD is considered a phenocopy of AIDs.¹⁰ However, there is no correlation between autoantibodies and the activity and severity of cGVHD,³⁰ and pathogenic autoantibodies have not been identified. Not only does cGVHD mimic SSc, but the development of many typical AIDs with autoantibodies one month to 4.5 years after BMT has been reported.³¹ Both cGVHD, which develops three months to several years after BMT,¹⁰ and post-BMT AIDs (pBMT-AIDs) are triggered by BMT and have similar onset times. cGVHD is not just a phenocopy of AIDs and may have the same etiology. Therefore, gender bias in cGVHD and AIDs may be due to the same etiology. It is thought that cGVHD that develops after BMT, which ablates the recipient's bone marrow as a pretreatment, occurs between BMC and Soc, which are allogeneic relationships. Therefore, the etiology of AIDs may also be due to BMC and Soc in an allogeneic relationship brought about by natural Mc.

X chromosome and sex hormone When the etiological hypotheses of AIDs cannot clearly and directly explain gender bias, the sex hormone and sex chromosome involvement theories are constantly relied on. When considering the gender bias of AIDs, we cannot but pay attention to the sex chromosomes, especially the X chromosome. Therefore, Turner's syndrome (TS) and

Klinefelter's syndrome (KS) caused by sex chromosome nondisjunction are suitable research subjects. The karyotype of TS is mainly 45, XO, which is X monosomy, and 46, X, i(Xq), which lacks the short arm of the X chromosome, and KS is 47, XXY.^{32,33} The incidence rate of AIDs in KS males is higher than in general males, indicating a risk comparable to that in general females.³⁴ In addition, the prevalence of KS was higher in SLE males than in general males.³⁵ From gene-dose theory, the incidence of AIDs in TS females was expected to be about the same as that of XY males, but the actual risk is twice that of the general females and 3.9 times higher in male-dominant AIDs.³⁶ Usually, one X chromosome of XX females is inactivated (i.e., X chromosome inactivation, XCI) except for the PAR region at the tip of the short arm, so the gene dosage on the X chromosome is the same for XX females, XO females, XY males, and XXY males. However, some genes escape XCI, resulting in an imbalance in the amount of the X gene. There is a theory that XCI escape is the cause of the increase in AIDs in KS,³⁷ but this cannot be applied to TS. There is also a theory that the lack of PAR region is the cause of the increase in AIDs in TS,³⁶ but this cannot be applied to KS. There are many reports that among the sex hormones, estrogen and progesterone promote autoimmunity, while androgen works protectively, which is the basis for the female predominance of AIDs.³⁸ Insufficient secretion of female hormones is observed in TS and male hormones in KS.^{32,33} The cause of the increase in AIDs in KS can be explained by male hormone insufficiency, but the sex hormone theory collapses due to the presence of TS. From the above, the X chromosome and sex hormones cannot explain the gender bias of AIDs. Recently, it has been reported that the intestinal microbiota is involved in developing AIDs by affecting sex hormones.³⁹ However, while it may modulate the pathogenesis, it is unlikely to be the primary cause of gender bias. It seems that the etiology hypothesis of AIDs needs to be able to explain gender bias without relying on X chromosomes and sex hormones.

Although TS and KS seem to have nothing in common regarding the increased incidence of AIDs, the phenotype common to both is hypogonadism.^{32,33} In fact, castration in male non-obese diabetes mice, a model of human autoimmune diabetes, significantly increases the prevalence of the disease,⁴⁰ and 4 to 30% of females with premature ovarian insufficiency (POI) who show estrogen deficiency have AIDs coexistence.⁴¹ In addition, a prospective study of POI patients without AIDs and X-chromosome abnormalities found 40.4% to develop AIDs.⁴² From the above facts, it is clear that AIDs development is accelerated by genital dysgenesis, defect and disease in both sexes, regardless of sex chromosomes or sex hormones. It is suggested that the reproductive organs may secrete some humoral factor other than sex hormones that suppresses the development of AIDs.

Trigger of AID

Destruction Vaccines, wounds, drug disorders, infections, etc., are considered to be triggers for AIDs. There are cases where AIDs develop after vaccination. Usually, an adjuvant is added to the vaccine to enhance its efficacy. The effect of adjuvant is said to be that the released cell contents by damaging the cells activate the immune system. Post-vaccine AIDs are thought to be due to this adjuvant's action rather than the vaccine itself.⁴³ Lens-induced uveitis and sympathetic ophthalmia (SO) develop after lens and eyeball damage due to trauma and surgery. Usually, the eye has an immune privilege and is protected from the immune system. However, it is said that the lens and eyeball proteins leaked by injury are exposed to the immune system, and autoimmune uveitis develops.⁴⁴ Anti-mitochondrial antibody (AMA) specific for PBC have been detected after acute liver failure due to an overdose of acetaminophen, but they are transient and do not cause PBC.⁴⁵ Acetaminophen-induced liver injury shows necrosis,⁴⁶ and there is no gender difference in the positive rate of AMA.⁴⁵

Many reports show that AIDs develops after bacterial, fungal, and viral infections. Molecular mimicry, endothelial cell damage, and superantigens have been proposed to explain the relationship between infectious pathogens and AIDs.⁴⁷ Recently, the hypothesis that pyroptosis (immune cells and some somatic cells)⁴⁸ and NETosis (neutrophil)^{49,50} as cell death for pathogen clearance is the etiology of AIDs has also been proposed. In addition, Pender et al. hypothesize that EBvirus-infected B cells and dysfunctional CD8⁺T cells cause autoimmunity.⁵¹ However, many reports show a rather male-dominated bias in infectious diseases,⁵² and none of the hypotheses seem to explain the female dominance of AIDs beyond male-dominated infectious diseases. As mentioned above, the development of many typical AIDs with autoantibodies after BMT has been reported.³¹ The immunosuppressed state after BMT becomes a battle against infectious diseases. The infection after BMT may be the trigger of pBMT-AIDs. Most cases of cGVHD have aGVHD as a precursor. cGVHD may not be a phenocopy of AIDs, but pBMT-AIDs triggered by aGVHD. The underlying mechanism of occurrence of cGVHD and pBMT-AIDs is the same, and the sites of trigger damage likely determine both phenotypes. Just as infections have a favorable age and organ depending on the pathogen, most AIDs also have a favorable age and organ. Among those showing multiple AIDs in the same organ and tissue, many have almost the same age of onset. For example, UC and CD involving the gastrointestinal tract are most common at ages 20-29, PBC and PSC involving the bile ducts are 30-49, and MS and GBS involving the myelin sheath are 30-45 years old.² Pathogen-infected cells exhibit cytolysis and inflammatory cell content release (i.e., pyroptosis).⁵³ The

favorable age of infection determines the onset age of AIDs, and the site and range of infection and the host's response to the released autoantigens determine the phenotype of AIDs. Infection is only a trigger, and there seems to be a factor determining gender bias of AIDs in the next step following the trigger. The common event for various triggers of the onset of AIDs and autoantibody production would be cell destruction and release of cell contents.

Regeneration Neurons in the central nervous system and myocardium are tissues with an extremely low prevalence of organ-specific AIDs. However they occupy a considerable volume in the human body and trigger infectious diseases are not uncommon. Multiple sclerosis (MS) is representative of the AIDs of the cranial nervous system, but it is a disease of the myelin sheath.⁵⁴ Guillain-Barre syndrome (GBS) has not only a demyelinating type but also an axonal type, but it is a peripheral neuropathy.⁵⁵ Autoimmune encephalitis (AE) includes Hashimoto's encephalopathy (HE), autoimmune disseminated encephalomyelitis (ADEM), limbic encephalitis (LE), etc. HE is a disease that is concurrent with Hashimoto's disease, and ADEM is a demyelinating disease.⁵⁶ LE has a low prevalence rate of 2.0/100,000 and is mainly associated with tumors.^{57,58} There are few cases of AE where purely neurons primarily cause inflammation. Autoimmune myocarditis (AMC) includes dilated cardiomyopathy (DCM), giant cell myocarditis (GCM), eosinophilic myocarditis (EM), etc. DCM is to the extent that autoimmune mechanisms are considered as one of the causes,⁵⁹ while GCM and EM are mainly secondary to collagen disease,⁶⁰ and the prevalence is also low.^{61,62} The brain has immune privilege, and the immune system in the brain is suppressed, so it was thought that no immune response would occur, but recent research has shown that it is subject to immune surveillance.⁶³ The prevalence of MS, an AID of the myelin sheath in the central nerve, is not low at 58.3/100,000. The myocardium is not an immune privilege tissue, and the low prevalence of AIDs in neurons and myocardium are unlikely to be due to a suppressive immune system. The myelin sheath has a robust regenerative capacity,⁶⁴ and peripheral nerves have some regenerative capacity, whereas neurons in the central nervous system do not.⁶⁵ Myocardium also has little regenerative capacity.⁶⁶ Cell regeneration may be necessary for the onset of AIDs. The lack of regenerative capacity in two major organs, which are extremely important for the survival of animals, may be due to the more significant disadvantages than the benefits associated with regeneration. From the above, it is considered that the development of AIDs requires cell destruction and regeneration.

Mesenchymal stem cells MSC is a self-renewing multipotent stem cells that can differentiate not only into mesoderm but also into ectoderm and endoderm. MSC promotes anti-inflammatory effects and tolerance induction by cooperating with immune cells at the inflammatory site⁶⁷ and is involved in cell repair and regeneration.⁶⁸ MSC can also be differentiated into pancreatic β cells,⁶⁹ and there is a report that pancreatic β cells are replaced by chimeric cells in type 1 DM.⁷⁰ Recipient Soc was likely replaced with chimeric Soc by the chimeric MSC. In neurons and myocardium, where there is little regeneration, regenerative replacement by male chimeric MSC rarely occurs, so it is predicted that the incidence of AIDs will be low in females. In fact, GBS and DCM are male-dominated.² Bone marrow-derived MSC can also be differentiated into fibroblast and plays a vital role in wound healing and skin repair.⁷¹ Fibrotic lesions in SSc result from excessive extracellular matrix synthesis by locally abnormally activated fibroblasts.⁷² Therefore, the target cells of systemic AIDs (i.e., collagen or connective tissue disease), such as SSc and SLE, would be fibrocytes differentiated and replaced by bone marrow MSC. MSC has no expression of HLA class II, and the expression of HLA class I is low, so it is immune-privileged, and the risk of rejection is low.⁷³ Therefore, male MSC is unlikely to be attacked by female LLBMC. In addition, MSC has not only tissue repair ability but also immunosuppressive and anti-inflammatory effects, so it is used for transplant treatment of GVHD and AIDs, and a certain alleviation effect is recognized.⁷⁴ However, in this simulation, it is inferred that the transplantation of male MSCs to a female patient may cause the development of AIDs. In fact, there is a report that no significant difference in an MSC transplantation trial of 192 GVHD patients was observed in the clinical outcome compared to controls, and there is also a report of exacerbation of Crohn's disease and recurrence of.⁷⁴

In the simulation, the assumption that chimeric Soc replaced tissue Soc by chimeric MSC and female LLBMC attacked male Soc matched well with the gender bias and incidence rates of cGVHD and AIDs except for group 3, where adult males dominate. What gives AIDs and cGVHD gender bias is the combination of gender in effector cells and target cells. This result is considered to support the Mc cause theory of AIDs strongly. However, what has been clarified this time is only a part of the missing link from Mc to AIDs, and which cells among female LLBMC are effector cells and what is the target factor of male Soc remain a mystery.

Target factor

From the result that female LLBMC is attacking male Soc, it is most likely that females are exposed and sensitized to male cell-specific molecules. In the case of human females, who are internally fertilizing species and placental mammals, the only opportunities for sensitization would be male pregnancy or sperm. GVHD that develops after major HLA-matched BMT (or HSCT) is thought to be caused by minor histocompatibility antigen (mHA) mismatch. In addition, there are many reports

that H-Y antigen (H-Y Ag) in mHA is the cause of the highest incidence of cGVHD in the combination of female donor/male recipient.^{12,75,76} mHA is a major HLA-presented peptide recognized as non-self by alloimmunity.⁷⁷ H-Y Ag encoded by six genes on the Y chromosome, which exhibits an amino acid sequence different from the peptide derived from the X homologous gene, is a molecule specific to male cells presented by HLA class I or HLA class II and is recognized as non-self by female B, T cells.⁷⁸ There are no male Soc-specific proteins among the autoantigens detected to date. H-Y Ag is the only molecule expressed explicitly in male Soc, and the molecule of male Soc that female LLBMC can target is H-Y Ag.

Effector factor

Anti-H-Y antibody (H-Y Ab) H-Y Ab was positive in 7.8% of healthy males and 41.4~49% of healthy females.^{75,79} Nakasone et al. measured six types of H-Y Ab in 136 F→M HSCT patients, detected at least one in 57% three months after HSCT, and developed cGVHD in 61%, suggesting a significant correlation between the presence of H-Y Ab and the incidence of cGVHD. Since H-Y Ab are detected three months or more after HSCT, they note that it coincides with the onset of cGVHD, although the association with aGVHD is low.⁷⁹ Miklos et al. also measured five types of H-Y Ab and detected H-Y Ab four months after HSCT, with 52% in F→M and 8.7% in M→M, and observed that the incidence of cGVHD was significantly higher in H-Y Ab-positive patients compared to negative patients. However, there was no correlation with aGVHD.⁷⁵ Sahaf et al. detected B cells (DBY-2-B cells) expressing DBY-2 (one of the H-Y Ag) specific BCR in 28 F→M HSCT patients by FACS and found that 16 patients (57%) were positive. 15 (94%) of 16 DBY-2-B cells positive and 5 (42%) of 12 DBY-2-B cells negative developed cGVHD, suggesting that H-Y Ag-specific B cells are involved in the development of cGVHD.⁸⁰ Mismatch of mHA (HA-1, CD30) other than H-Y antigen between donor and recipient was a risk factor for the development of aGVHD after HSCT but was not associated with cGVHD.^{81,82} The above suggested that the H-Y Ab is involved in the bias of cGVHD incidence due to the gender combination of donor/recipient. However, Nakasone et al. found that the H-Y Ab of female donors and male recipients after HSCT had a low matching rate of corresponding antigens, suggesting that it is produced de novo by naive B cells (derived from chimeric HSC?) sensitized by H-Y Ag.⁷⁹

Long-lived memory plasma cells (LLMPC) As mentioned above, the development of many typical AIDs with autoantibodies after BMT has been reported.³¹ Observation of before and after the onset of pBMT-AIDs within the reset immune environment of the recipient, achieved through strong pretreatment in BMT, provides crucial insights into the development of AIDs. After BMT, the patient has severe immunosuppression due to immunosuppressants, including steroids. In addition, it has been observed that highly suppressive Treg subsets are increased in patients receiving methylprednisolone, commonly used during transplantation.⁸³ Since pBMT-AIDs develops in a robust immunosuppressive state in which Treg functions well after BMT, the effector cells of pBMT-AIDs are thought to be resistant to immunosuppressants and Treg.

The effector factor that can recognize the H-Y Ag presented on the HLA class I of male Soc is probably H-Y Ab, H-Y Ag-specific BCR, and H-Y Ag-specific TCR. There is a report that antibodies can also bind to antigens on HLA molecules.⁸⁴ As mentioned above, the effector cells in BMC are LLBMC (HSC, MSC, long-lived memory T, B cells), excluding mature lymphocytes. H-Y Ag-specific long-lived memory plasma cells (H-Y-LLMPC) and H-Y Ag-specific long-lived memory T cells (H-Y-LLMTC) hold these factors. Both LLMPC and LLMTC are present in the bone marrow. As mentioned above, the etiology of cGVHD is thought to be primarily in cells of the B cell lineage. LLMPC exists not only in the bone marrow, which is the central niche, but also in inflammatory tissues and is maintained by supporting inflammatory cells.^{15,85} Maternal Mc cells have been detected in bone marrow and organs in SSC patient who has not been detected four times in peripheral blood.⁸⁶ LLMPC is a non-proliferative cell that has a lifespan of several months to decades and secretes highly-affinity class-switched antibodies in the bone marrow.¹⁵ Compared to aGVHD, cGVHD is less responsive to immunosuppressants, including steroids,⁸⁷ and AIDs also have a limited effect on immunosuppressants.⁸⁸ Even B cell depletion therapy has a certain effect on cGVHD and AIDs, but it is limited.^{89,90} LLMPC is resistant to steroids, immunosuppressants, cytotoxic agents, radiation, and B cell depletion therapy.⁸⁵ LLMPC maintenance does not require T cell involvement,¹⁵ so there may be no Treg suppression. Administration of CD20 monoclonal antibody to mice successfully depleted B cells and memory B cells but did not affect LLMPC with less expression of CD20 and immunoglobulin levels.⁹¹ By continuously secreting pathogenic antibodies, LLMPC may support the chronic inflammatory process of AIDs and contribute to symptom flares.⁸⁵ Based on the above, the effector cells of cGVHD and AIDs are highly likely to be H-Y-LLMPC. In Females, target cells are male Soc replaced by male chimeric MSC, and effector cells are female H-Y-LLMPC from self or maternal Mc. In males, target cells are own male Soc, and effector cells are female chimeric H-Y-LLMPC.

Is H-Y Ab a pathogenic antibody? This simulation is performed on the premise that cGVHD and AIDs are based on the same Mc mechanism, and a solution was obtained that could explain the gender bias of both. However, a contradiction occurs if cGVHD and AIDs are based on the direct

action of H-Y-specific B and T cells. Because there have been no reports that the H-Y Ab shows antibody transfer AIDs, that the H-Y gene mutation shows phenocopy of AIDs, and that the H-Y Ab is a pathogenic autoantibody for AIDs. The fetus and placenta retain immune privilege. Immune privilege refers to the state of organs and tissues protected from the immune system, including not only the fetus and placenta but also the central nervous system, the anterior chamber of the eye, hair follicles, testes, stem cells and cancer cells. As a way to acquire this state, there is a passive form due to the low or no presentation of HLA molecules and active regulation by suppressing the immune response to the target antigen.⁹² H-Y Ag-specific CD8⁺T cells were detected during male pregnancies.⁹³ The H-Y antibody positive rate in patients with secondary recurrent miscarriage was significantly higher than in controls, and the male birth rate of positive females was low.⁹⁴ It seems to be true that the H-Y Ab is a pathogenic antibody. However, most male fetal pregnancies continue due to the functioning of the immune tolerance systems that protect the fetus, such as the scarcity of HLA class I expression on placental trophoblasts,⁹⁵ the elevation of Treg in maternal blood,⁹⁶ and the production of anti-idiotype antibodies,⁹⁷ etc. As mentioned above, nearly 50% of female donors carry H-Y Ab,^{75,79} and mHA mismatches other than H-Y Ag are involved in early aGVHD onset after HSCT,^{81,82} H-Y Ab does not appear until three to four months at the onset of cGVHD,^{75,79} and there is little similarity in H-Y Ab between female donor and male recipient.⁷⁹ The most frequently expressed H-Y Ab in male recipients after F→M HSCT was DBY-Ab,⁷⁵ but not only DBY-Ab but also other H-Y Ab did not correlate with the presence or absence of individual antibodies and the incidence of cGVHD.⁷⁹ These facts may indicate that H-Y Ab is not only suppressed by H-Y Ab specific anti-idiotype antibodies but also the production of H-Y Ab that is an autoantibody for male recipients is strongly suppressed. In contrast, only H-Y Ab that is an anti-non-self Ag antibody escapes suppression. In other words, H-Y Ab, H-Y specific B cells or LLMPC from female donors are transferred to male recipients, but a robust immune tolerance system may suppress their expression. As a result, no H-Y Ab can recognize the male recipient H-Y Ag, but how can H-Y Ab exhibit pathogenicity and develop cGVHD? Since B cell depletion therapy for AIDs exerts a certain effect without affecting the blood autoantibody concentration, it is believed that B cells are involved in the pathogenesis of AIDs not only in autoantibody production but also in antibody-independent functions such as antigen presentation, cytokine production, and immune regulation.⁹⁸ However, as mentioned above, pBMT-AIDs with autoantibodies develops in a situation where Treg is increased after BMT,⁸³ so it is possible that LLMPC resistant to B cell depletion therapy and Treg, not B cells, are involved in the development of AIDs with antibody-independent functions. Furthermore, the fact that there was a significant correlation between the H-Y Ab positive rate and the incidence of cGVHD⁷⁹ suggests that the H-Y Ab may have a non-directly impaired effect. H-Y Ag as a target molecule and H-Y Ab as an effector factor seem to be a missing link between Mc and AIDs. However, it does not seem to be explained by a simple antigen-antibody reaction, and it is necessary to review the findings in AIDs research further.

Autoantibody and autoantigen

AIDs and autoantibodies Hayter et al. reviewed 81 AIDs, of which 45 (56%) had well-defined autoantigens, and among the 51 autoantigens, 28 (55%) were classified as highly pathogenic. They also found that only 8 of 36 tissue-specific AIDs with well-defined autoantigens showed antibody transfer disease, and only 19 showed phenocopy due to mutations in autoantigen genes. Based on these results, they recommend that the presence of phenocopy hereditary disease in a single autoantigenic AID should be added to the diagnostic criteria of AIDs.² Based on the existence of pathogenic autoantibodies and experiments on the reproduction of phenocopy using autoantigen genes, it is likely that some autoantibodies are clearly involved in the phenotype of AIDs. Indeed, the prevalence of AIDs with well-defined autoantigens is high (Fig. 1), but it cannot be ignored that 44% of AIDs do not have well-defined autoantigens. Autoantibodies have not been identified even in diseases thought to develop by an autoimmune mechanism after apparent trigger, such as aforementioned autoimmune uveitis.⁴⁴ In addition, autoantibodies were also detected in 62% of cGVHD, which is considered to be a phenocopy of AIDs. However, there was no correlation between autoantibodies and cGVHD activity or severity,³⁰ and no pathogenic autoantibodies have been identified. Males after vasectomy have seen the appearance of autoantibodies at a high rate, but AIDs has not developed.⁹⁹ Anti-mitochondrial antibodies have been detected after acetaminophen liver injury, but no PBC occurred.⁴⁵ B cell depletion therapy for AIDs has a certain effect without affecting the blood autoantibody concentration.⁹⁸ Cincinelli et al. found that antinuclear antibody was detected at a high rate of 18.1% in the general population, with a significantly lower female predominance than connective tissue diseases. They concluded that autoantibody production alone cannot explain the pathology and pathogenesis of AIDs.¹⁰⁰ Although autoantibodies are inseparable from AIDs, there is no denying the possibility that pathogenic autoantibodies are not directly related to the pathogenesis of AIDs, act as mere secondary modifiers, increasing the prevalence by intensifying the symptoms and contributing to the improvement of the diagnostic rate.

Features of autoantigens As a feature of these well-defined autoantigens, 80% is tissue-specific,

57.8% has a membrane-binding protein, 33.3% has a repeat domain, and 35.6% has a coiled-coil sequence, which is higher than the proportion in the human proteome. It has been shown that autoantigens are not a random selection.² There is a hypothesis that autoantibodies are caused by molecular mimicry of the pathogen protein epitope.⁴⁷ Regarding tissue-specific and membrane-binding proteins, there is a possibility that positive selective pressure is exerted on pathogen proteins because proteins that are more likely to be bound by host autoantibodies are more advantageous for pathogens to mimic. However, since housekeeping proteins have more varieties than tissue-specific proteins and are more advantageous for mimicking, selecting of tissue-specific proteins may depend on host-side factors. In addition, membrane-binding proteins are often glycosylated by post-translational modification,¹⁰¹ and the immunogenicity of glycosylated proteins increases.¹⁰² However, the enhancement of immunogenicity is not directly related to the enhancement of affinity with antibodies, that is, antigenicity. The selection of membrane-bound proteins may be due to a factor on the host side that it is easy to produce antibodies rather than the result of being mimicked. Repeat domains such as tetratricopeptide repeat (TPR), ankyrin repeat, and leucine-rich repeat provide flexible binding to multiple binding partners and are involved in cell cycle regulation, transcriptional regulation, protein transport, protein folding support, etc. The target binding affinity of these domains is equivalent to that of antibodies, and their binding properties have been exploited to create high-affinity binders as an alternative to antibodies.¹⁰³ The coiled-coil sequence is also involved in protein-to-protein interactions.¹⁰⁴ The selection of repeat domains and coiled-coil sequences is also likely due to intrinsic necessity rather than extrinsic chance due to molecular mimicry. These facts suggest that some protein may mediate autoantibody production.

anti-sperm antibody (ASA)

ASA and H-Y Ab Females are sensitized not only by male pregnancies but also by sperm male-specific antigens, including H-Y Ag. Spermatogenesis begins after puberty, so sperm are absent during the fetal period.¹⁰⁵ Therefore, it is after puberty that females are sensitized by sperm. When the barrier of an immune-privileged organ is destroyed by trauma, surgery, inflammation, etc., sequestered antigens exposed to the immune system induce an immune response.¹⁰⁶ The exposed antigen has a strong immunogenicity because immune tolerance is not established. Testis also develops autoimmune orchitis when the blood-testis barrier is disrupted.¹⁰⁷ The specificity of the testis is that it presents antigens outside the barrier in the form of sperm. Of the 27 infertile females who habitually had vaginal intercourse during menstruation, 22.2% were positive for ASA, significantly higher than the 3.3% positive among 30 infertile females without that habit.¹⁰⁸ It suggests that sensitization by sperm may be enhanced in conditions such as menstruation in which the protective response of the mucosal epithelium of the female reproductive tract is declining. Many testis-specific antigens (TSA) are also expressed in cancer cells and belong to cancer-testis antigen (CTA). CTA with strong immunogenicity is used as a target for cancer immunotherapy. Sperm express sperm-specific antigens (SSA) that are part of the TSA and cause the production of ASA. ASA is detected by an indirect immunofluorescent antibody method using sperm or an indirect immunobead method, but SSA and H-Y antigens cannot be distinguished. However, ELISA or microarray can detect H-Y Ab using recombinant H-Y protein. Eighteen sperm-associated antigens (SPAG1~18) have been identified by two-dimensional electrophoresis of sperm membrane proteins and immunoblotting with ASA-positive seminal plasma in unexplained infertile males.¹⁰⁹ SPAG1, 6, 8, 15 and 17 are mainly expressed in the testis; others are ubiquitous, but none are specifically expressed exclusively in male. SPAG does not contain H-Y antigen.¹⁰⁹ As mentioned above, 7.8% of healthy males are H-Y Ab positive.⁷⁵ Even if H-Y Ab exist in males, they may not be pathogenic. ASA is formed in 50% of men (2% in control) due to continued sperm absorption by epididymal or ejaculatory duct obstruction, and is still detectable 20 years after vasectomy. ASA-induced infertility is common after vasovasostomy.¹¹¹ ASA is detected in 72.1% of females with unexplained infertility. ASA is regarded as a cause of infertility as a sperm immobilization antibody¹¹² and can be said to be a pathogenic antibody. The corresponding antigen of ASA detected in females is unknown, but it is presumed mainly SPAG or H-Y Ag. Tung et al. detected ASA in 90% of prepubertal males and females by immunofluorescence. Although it decreased to 60% after that, it persisted throughout life, suggesting that ASA production may be due to molecular mimicry.¹¹³ However, maternal SSA-specific LLMPC sensitized by sperm or male pregnancies may have been transferred as Mc cells.

ASA and autoantibodies Autoantibodies other than ASA are also produced after vasectomy. Lucas et al. detected ASA at 64%, antinuclear Ab at 78%, antithyroglobulin Ab at 12% after vasectomy, and autoantibodies that respond to various tissue antigens by indirect immunofluorescence method are detected with a weak but significant difference.¹¹⁴ Mathews et al. also found increases in antinuclear Ab, anti-smooth muscle Ab, antimitochondrial Ab, etc., after vasectomy, but no significant increase in AIDs.⁹⁹ Vasectomy may be a trigger for autoantibody production other than ASA. Baker et al. detected anti-microsome antibodies in 11.8% of 102 infertile males with ASA-positive who had not undergone vasectomy, a significant difference compared with 4.3% of 277 infertile males with ASA-negative, suggesting effects of genetic predisposition of sperm in

autoimmunity.¹¹⁵ Soares et al. detected ASA in 40% of 35 men with SLE.¹¹⁶ D'Cruz et al. detected ASA in 15.2% of 33 SLE patients, antinuclear antibodies in 17.2%, anti-DNA antibodies in 27.6%, and anti-dsDNA antibodies in 6.9% of 29 ASA-positive patients excluding SLE.¹¹⁷ SSA, including H-Y Ag, induces ASA in many males and females regardless of age and is likely to be related not only to the production of other autoantibodies but also to the development of AIDs.

Apoptosis and necrosis

AIDs and mitophagy Previously, apoptosis has been considered as cell death of tissue damage caused by the direct action of autoreactive T cells and pathogenic autoantibodies in AIDs. However, it is said that apoptotic cells that arise in autoimmune reactions usually do not induce inflammation and are even anti-inflammatory.¹¹⁸ In recent years, mitophagy, the autophagy of mitochondria, has attracted attention and the elucidation of its mechanism is progressing.¹¹⁹ The dysfunction of mitochondria plays a vital role in the pathogenesis of SLE.¹²⁰ Autophagy inhibitors improve SLE, RA, and MS.¹²¹ When acteoside, a mitophagy inhibitor with anti-inflammatory and neuroprotective properties, was administered to experimental autoimmune encephalomyelitis (EAE) model mice, it inhibited excessive neuronal mitophagy and reduced the progression and exacerbation of EAE.¹²² A study using cultured bile duct epithelial cells of PBC indicated that autophagy may mediate the aging process of the bile duct epithelium and be involved in the pathogenesis of bile duct lesions.¹²³ Mitophagy may be involved in the development and progression of AIDs. Xia et al. demonstrated that the oncolytic measles virus infects lung cancer cells, inducing mitophagy and suppressing apoptosis through decreased cytochrome c release, which favors viral replication, and ultimately, cancer cells undergo necrosis due to ATP depletion.¹²⁴ It indicates that the final form of mitoptosis due to excessive mitophagy may be necrosis, not apoptosis.

AIDs and necrosis Autoimmune lymphoproliferative syndrome (ALPS), which is caused by defective genes for proteins involved in apoptosis such as Fas, Fas ligand, and caspase10, etc., develops AIDs with autoantibody production.¹²⁵ Fas and FasL gene-mutated *lpr* and *gld* mice develop autoantibody production, SLE-like AIDs, and glomerulonephritis.¹²⁶ At least antibody production may not require an apoptotic body. Knockout mice of MFG-E8 protein, which is involved in the recognition of phosphatidylserine that is an eat-me signal of apoptotic cells, produce anti-dsDNA antibodies and anti-nuclear antibodies and develop glomerulonephritis.¹²⁷ It is suggested that impaired clearance of apoptotic cells is involved in the onset of AIDs. However, the fact that antibodies were produced despite impaired clearance also means that the clearance process of apoptotic cells may not be involved in antibody production. Apoptotic cells, which are not cleared in the environment of phagocytes that have lost their phagocytic ability, cause secondary necrosis, the cell membrane collapses and release the contents. Accumulation of non-phagocytosed apoptotic cells in the germinal centers of the lymph nodes of some SLE patients has been observed, and it has been pointed out that apoptotic cells due to lack of clearance and their secondary necrosis may be one of the etiologies of SLE.¹²⁸ Therefore, in the MFG-E8 knockout mouse, it is not the accumulated apoptotic body but the cellular contents released by secondary necrosis that promote autoantibody production.

Among paraneoplastic AIDs, there is ovarian teratoma-associated anti-NMDA receptor antibodies encephalitis (NMDAR encephalitis).¹²⁹ Teratoma is a tumor containing all three blastodermic layers. When it contains a receptor on the nerve cell membrane of the brain tissue, it produces an antibody that binds to the receptor and develops a central nervous system disorder. Even though there is no problem with the cranial nerves, the pathogenic autoantibodies can damage them remotely. The cell death of the tumor shows the swelling of organelles due to ATP depletion and the release of inflammatory cell contents due to the destruction of cell membranes (i.e., oncosis),⁵³ which is similar to necrosis in terms of destruction of cell membranes. Since surgical removal of the teratoma cures encephalitis, cutting off the source of autoantigens appears to prevent the persistence of autoimmune disorders. This fact may mean that a device that provides antigens by necrosis is necessary for the inflammation to persist even in usual AIDs. The effects of recently developed photoimmunotherapy against cancer are said to be due not only to the immunogenic cell death (necrosis) of cancer cells caused by near-infrared light, but also to the activation of multiclonal immune responses by the released cancer cell contents.¹³⁰ As mentioned earlier, the infection considered to be a trigger for AIDs leads to pyroptosis, which is characterized by cytolysis and the release of inflammatory cellular contents.⁵³ From the above, there is no involvement of pathogenic autoantibodies and associated apoptosis in the etiology and autoantibody production of AIDs, and another mechanism involving mitophagy-induced necrosis (i.e., mitoptosis) and continuous supply of autoantigens may be hidden. Is it possible that the result of the reaction between male Soc presenting H-Y antigen and female H-Y-LLMPC targeting it can be necrosis instead of apoptosis?

Antibody production against endogenous antigens

Endogenous antigens and exogenous antigens In order for B cells to produce anti-A antibodies against tissue-specific autoantigen A, the action of effector CD4⁺T cells activated by antigen A is usually required. For naive CD4⁺T cells that have escaped negative selection against antigen A to

be activated and differentiate into antigen A-specific effector CD4⁺T cells, antigen A presented on the HLA class II molecules of dendritic cells (DC) is necessary. Exogenous antigens are usually presented by HLA class II molecules, and autoantigens, which are endogenous proteins, are presented by HLA class I. DC can also present endogenous antigens by HLA class II molecules by cross-presentation, but organ-specific proteins, which account for 80% of autoantigens,² are not expressed in DC without the expression of AIRE protein found in medullary thymic epithelial cells (mTEC). In order to present endogenous antigen A by HLA class II, DC must be internalized it as exogenous antigens.

Immune complex (IC) and complement Complement is activated mainly by binding to the Fc portion of antibodies of IC and causes cell and tissue damage as an opsonin, chemotactic factor, membrane invasion complex, and chemical mediator-releasing factor.¹³¹ All humans with C1q deficiency develop severe SLE, and C1q-deficient mice also exhibit an SLE-like phenotype,¹³² so the complement is thought to be working defensively against tissue damage caused by autoimmunity. However, the lack of processing process of IC due to the opsonizing effect of complement did not enhance the pathological condition of SLE but rather caused SLE to develop spontaneously de novo, suggesting that IC is not only the result of AIDs but also the cause of AIDs onset or autoantibody production.

Fcγ receptor (FcγR) The *FCGR* gene, which codes Fcγ receptors (FcγR), is identified as a disease-susceptibility gene in many AIDs.^{133,134} APC takes up extracellular substances using receptors on the cell membrane. It is the Fc receptor (FcR) and complement receptor (CR) that are involved in the uptake of opsonized antigens by antibodies and complements.¹³⁵ FcγR is involved in the phagocytosis of antigens captured by IgG and antigen presentation and is expressed on the membranes of various hematopoietic cells.¹³³ FcγR has activating subtypes (FcγRIa, IIa, IIc, III a, IIIb) and an inhibitory subtype (FcγRIIb) in cell function through intracellular signal molecules, and it is said that the balance between these subtypes regulates immune responses. However, many unclear points exist, such as the development of AIDs and autoantibody production. FcγRIa, IIa, IIb, IIIa are expressed in DC. FcγRs are not expressed on T cells, and only FcγRIIb is expressed in B cells.^{133,136} A study of FcγRIIa polymorphisms has shown a strong correlation with etiology, onset, and increase of susceptibility of several AIDs, particularly SLE and RA. Furthermore, human FcγRIIa transgenic mice (no FcγRIIa expression in mice) showed the onset of RA and SLE with antinuclear antibodies, suggesting that FcγRIIa plays a vital role in the activation of inflammation and antibody production in AIDs.¹³⁷ FcγRIIb is suppressive to autoantibody production, but like other FcγRs, it is involved in IC phagocytosis and antigen presentation.¹³³ Therefore, DC can internalize and present autoantigen A in the form of IC using FcγR Ia, IIa, IIb, and IIIa, and autoantigen A-specific B cells can do so using FcγRIIb or BCR. AIDs with *FCGR 1A, 2A, 2B, and 3A* as disease susceptibility genes include SLE, RA, MS, SjS, ITP, GBS, MPA, WG, UC, TA, and KD.^{133,134,138-140}

FcγR and HLA class II HLA allele is the most common disease-susceptibility gene of AIDs, and among them, the HLA class II allele is considered to be AIDs susceptibility HLA.^{141,142} However, it is still unclear how the HLA allele, especially the class II allele, is involved in developing AIDs. Is HLA class II, which presents exogenous antigens, more susceptible to AIDs than HLA class I, which is the target of autoimmunity? Some attempts have been made to understand the disease susceptibility of HLA class II based on the idea that pathogen peptides presented on HLA class II of APC activate naive CD4⁺T cells through molecular mimicry with autoantigens.⁴⁷ However, as mentioned above, it is difficult to explain all autoantibody production by molecular mimicry. There are also attempts to explain cell damage caused by autoantibodies by aberrant HLA class II expression in diseased tissue.¹⁴³ However, this has not been demonstrated in many AIDs. Many AIDs with disease susceptibility to the HLA class II allele have autoantibodies. In contrast, AIDs with only class I tend not to have well-defined autoantibodies.¹⁴⁴ These findings suggest that HLA class II molecules in AIDs increase susceptibility by being involved in autoantibody production, while HLA class I molecules that present autoantigen may not be directly involved in the development of disease after trigger. Among the above AIDs that have the *FCGR* gene as a disease-susceptibility gene, only KD, which do not have autoantibodies, are not susceptible to HLA class II allele.^{138,139,144-148} If IC uptake by FcγR and antigen presentation by HLA class II are not independent events but a series of antigen priming and presentation process events, the possibility that the process is involved in autoantibody production arises. That is, IgG antibodies bound to endogenous protein A released from necrotic cells are captured by FcγR on immature DC, internalized, processed, and presented as antigen A by HLA class II molecules. The naive CD4⁺T cells that recognize it differentiate into effector CD4⁺T cells and activate antigen A-specific B cells which take in antigen A with FcγR or BCR and presented it by HLA class II molecules. However, at least until an anti-A antibody is produced, the IgG antibody that binds to antigen A is not an anti-A antibody, so that some protein will mediate between the antigen A and the IgG antibody, but is it possible?

Aging of effector cells and target cells

Immunosenescence is said to not only increase cancer and infectious diseases due to a decline in normal immune responses but also enhance chronic inflammation and autoimmune responses.¹⁴⁹ This fact may be related to middle-aged onset AIDs, but they are rare to develop in older age. The number of MPC, which is a candidate for effector cell, decreases in the blood and bone marrow with age, and blood antibodies corresponding to some antigen-specific bone marrow MPC also decreases.¹⁷ MSC, a candidate for stem cells that provide target cells, also decreases in quantity and regenerative capacity with age, suggesting a relationship with individual aging.¹⁵⁰ Simulation assumes that both effector cells and target cells decline linearly with age. Males have no influx of new Mc cells after birth, and the Mc cells environment is determined at birth. Most target cells in males are self-Soc, so aging will have little impact. Female H-Y-LLMPC from grandmother, mother, and aunt via the mother as effector cells will likely decline in function after birth. As autoantibodies are produced after vasectomy, T and B cells derived from female chimeric HSC may become sensitized to their own sperm after puberty in males, but this is unlikely to affect prevalence. As a result of the interaction, the incidence of AIDs in males will decline with age. In females, effector cells will decline from birth, but H-Y-LLMPC increases after puberty due to sensitization by SSA and gradually declines after middle age. The chimeric male MSC as a target cell from the uncle and older brother via the grandmother and mother will decline with age, but it will increase rapidly due to male pregnancy in females, and then it will decline. As a result of the interaction, the onset of AIDs in females may increase gradually from puberty, increase further after male pregnancy, and gradually decrease after middle age. This simulation did not include the element of female sensitization by sperm, so an increase after puberty could not be confirmed, but other predictions were well consistent with the results of the ♀→♂ simulation. These predictions and simulation results are also consistent with the observations that GD increases after pregnancy,⁵ and the prevalence of AIDs is the highest at 20 to 29 years old.²

Therapy and reaction

As mentioned above, steroids, immunosuppressants, and molecular-targeted drugs against lymphocytes have a certain effect on AIDs, but their effects are limited,⁸⁸ so they are not curative drugs. An interesting finding is that zinc (Zn), and autophagy inhibitors have therapeutic effects on AIDs. The blood Zn concentration was significantly lower in patients with AIDs.^{151,152} Patients with oral lichen planus improved after administration of zinc acetate. Administration of Zn to experimental autoimmune encephalomyelitis (EAE) model mice significantly improved symptoms.¹⁵³ Zn is thought to stabilize Treg without suppressing the immune system.^{154,155} Zn deficiency induces mitophagy of porcine oocytes and increases reactive oxygen species, causing meiotic abnormalities.¹⁵⁶ Autophagy inhibitors improve SLE, RA, and MS,¹²¹ and mitophagy inhibitors reduce the progression and exacerbation of EAE.¹²² Enhancement of mitophagy may be involved in the development of AIDs, and the effect of Zn on AIDs is mediated through the inhibition of mitophagy.

Summary of the phenome of AIDs

Based on the results of this simulation, the author will summarize the phenome of AIDs that may connect the missing link from Mc to AIDs. The assumption that female LLBMC attacks male Soc could explain the gender bias and prevalence of AIDs in adults and youth. In females, the male Soc replaced by chimeric male MSC is attacked by own or chimeric female LLBMC, and in males, the own or chimeric male Soc is attacked by chimeric female LLBMC. H-Y Ag is likely to be the target factor of male Soc. It is highly possible that female H-Y Ag-specific LLMPC is the effector cell. However, it is unlikely that H-Y Ab is involved in developing AIDs as a pathogenic autoantibody. Destruction and regeneration of cells, mainly by infection, are necessary as triggers for the onset of AIDs. The sensitive organ and the favorable age of the pathogen determine those of the AIDs. Autoantibody production and maintenance of AIDs inflammation require autoantigen release by necrosis, not apoptotic cells. The autoantigen selection is not random and may be mediated by some protein. It is suggested that phagocytosis and antigen presentation of IC containing autoantigens by FcγR and HLA class II may be involved in autoantibody production. Moreover, the antibodies that form IC are not antibodies against autoantigens, and some protein may mediate them. ASA, including anti-H-Y antibody, which is found in many males and females regardless of age, is likely to be related to not only other autoantibody production but also the development of AIDs. There is no involvement of sex hormones or sex chromosomes in the gender bias of AIDs. However, it may be releasing humoral factors that downregulate the development of AIDs from the gonads. Immunosuppressants and B cell depletion therapy for AIDs have certain effects but are limited. The onset of AIDs may be related to the enhancement of mitophagy. Zn has a certain effect on AIDs, and the effect of Zn may be mediated by suppression of mitophagy. Are there any factors or mechanisms that can satisfy these phenome of AIDs? The author would like to present the hypothesis below.

Eri15/Spag1/Xt-mir axis

The author would like to present the exosome and Eri15/Spag1/Xt-mir axis as the mechanism to cause necrosis of male Soc with H-Y Ag as a target. Hayashida et al. reported that maternal mitochondrial DNA inheritance (MMI) is established through the elimination of sperm mitochondrial DNA due to the transport of the endogenous retroviral integrase 15 kD (Eri15) by the egg cytosol Spag1-2 via the SPAG1-1 protein on the sperm mitochondria outer membrane during fertilization.^{157,158} In addition, it was proved that hybrid male sterility (HMS) occurs due to mitophagy by malfunction of the MMI system, which is suppressed in the testes.¹⁵⁹ Furthermore, it was suggested that the Eri15/Spag1 axis is suppressed by micro RNA on the X chromosome (Xt-mir), mainly expressed in the testis.¹⁶⁰

As mentioned above, SPAG1 was discovered as one of the target proteins of ASA in unexplained infertile males.¹⁰⁹ SPAG1-1 is expressed in the mitochondrial outer membrane of sperm and glycosylated by post-translational modification in the epididymis,¹⁵⁷ so it has a high immunogenicity. Spag1-1 is a sperm-specific antigen and belongs to the cancer-testis antigen. SPAG1-2, a splicing variant of SPAG1-1, is widely expressed in the cytoplasm of organs other than sperm and provides a platform for quaternary protein folding of proteins via the TPR domain involved in protein-protein interaction as a member of the co-chaperone R2SP complex (SPAG1, PIH1D2, RUVB1/2).¹⁶¹ Both Spag1-1 and Spag1-2 are also expressed in cancer cells and stem cells, suggesting involvement in the Warburg effect by programmed mitophagy (mitochondrial quantity control).¹⁶⁰ Zeng et al. detected differentially methylated regions (DMRs) in ACPA (anti-citrullinated protein antibodies, RA-specific autoantibodies that correlate with disease severity)-related and RA-related epigenome-wide association studies (EWAS) in RA patients. They compared these DMRs-related protein-coding genes with the 295 associated genes in the RA-associated GWAS, identifying four genes that are duplicated in all. SPAG1 was included in these four genes.¹⁶² It is suggested that SPAG1 may be involved in the onset and progression of RA. In orbital fibroblasts of Active Graves ophthalmopathy (GO), the *SPAG1* gene was detected among hypermethylated genes compared to inactive GO.¹⁶³ Furthermore, 72 genes differentially expressed in fibroblasts of skin lesions of SSc compared to healthy people were detected, among which the *SPAG1* gene was recognized.¹⁶⁴ The involvement of SPAG1 in fibroproliferative AIDs is suggested.

Eri15 is an integrase that exists as a multimer in the cytoplasm not only in the ovaries but also in the testes and most somatic cells in mice. Eri15 is an integrase adapted to the mitochondria matrix environment, which is activated by Mn²⁺ and Mg²⁺ and suppressed by Zn²⁺. Eri15 is conversely suppressed by truncating the Zn²⁺ binding site required for regular integrase activity.¹⁵⁸ As mentioned above, the onset of AIDs may be associated with increased mitophagy. The therapeutic effects of Zn on AIDs¹⁵⁵ may be due to the suppression of mitophagy via Eri15. Mn²⁺ promotes mitophagy and induces mitochondrial dysfunction¹⁶⁵ (the effect of Mn on AIDs is unknown), and its effect on mitophagy may also be via Eri15.

Exosome and BCR

The exosome is a small vesicle surrounded by a lipid bilayer membrane, containing proteins, lipids, mRNAs, and microRNAs. It is released outside the cell and has attracted attention recently as an intercellular information transmission medium.¹⁶⁶ The Eri15/SPAG1 axis is used to avoid apoptosis by mitophagy during division in stem cells and cancer cells, so it is presumed to be an anti-apoptosis system.¹⁶⁰ Memory plasma cells (MPC) does not divide, but its differentiation and maintenance require autophagy and anti-apoptosis molecules.¹⁵ MPC may express Spag1-1 protein to utilize Eri15/SPAG1 axis as an anti-apoptotic system. Cytosolic proteins remain within the exosomes, and proteins derived from the plasma membrane are retained in the vesicle membrane.¹⁶⁷ SPAG1 protein (isoform unknown) has been detected in the exosome secreted by ovarian cancer cells.¹⁶⁸ If MPC expresses Spag1-1 protein, it is likely that it is contained in the exosome. It is said that exosome has a target cell. TCR/CD3 complex and BCR are detected on the surface of exosomes secreted from human T and B cells. It suggests transmitting specific signals to target cells with appropriate MHC/peptide combinations.^{169,170} There is a report that antibody can bind to the antigen on the HLA class II molecule,⁸⁴ so BCR may also be able to bind to antigen on the HLA class I molecule. H-Y Ag-specific MPC produces and releases an exosome with H-Y Ag-specific BCR on the surface and contains SPAG1-1 protein inside. The exosome binds to the H-Y Ag on the HLA class I molecule of the male Soc in which Spag1-2 protein and Eri15 protein are expressed. HLA class I molecules are internalized and recycled by endocytosis.¹⁷¹ The exosome is internalized with the HLA class I molecule. As mentioned above, male MSC is unlikely to be a target because HLA class I expression is low on MSC.⁷³ As a result, the Spag1-1 protein is incorporated into the mitochondrial outer membrane in the male Soc. The MMI system works, and the mitochondria that have lost their action potentials are processed by mitophagy. If it becomes excessive, necrosis will come as a result of mitoptosis. It has been observed that miR506, which belongs to Xt-mir and targets Spag1-2, is overexpressed in the bile duct epithelium of PBC.¹⁷² There is a possibility that negative feedback is working against excessive mitophagy by the HMS system in PBC. SPAG1-1 transported to the cytosol of target male Soc will also bind to SPAG1-2, which is bound to client protein as a co-chaperone.

Autoantibody

Affinity of SPAG1 to autoantigen As mentioned above, autoantigen selection may be mediated by some protein, and sperm-specific antigen (SSA) induces not only ASA but also other autoantibodies production.¹¹⁴ There may be a molecule that promotes autoantibody production in SSA, including SPAG. Molecular chaperones are most likely common molecules interacting with many autoantigen proteins to support protein folding. In addition, the membrane-binding protein, common among autoantigens, needs a molecular chaperone to be transported to the cell membrane after translation. Heat shock protein (HSP) is a typical molecular chaperone. It is a housekeeping protein well-preserved from bacteria to humans and works in all cells. HSP reacts efficiently with co-chaperones assistance.¹⁷³ As mentioned above, SPAG1-2, as a member of R2SP, binds to HSP via the TPR domain of SPAG1-2 to form a multi-chaperone complex and is involved in protein complex assembly.¹⁶¹ Repeat domains, including the TPR domain, and coiled-coil domains which are common in autoantigens, are involved in protein-protein interactions. The TPR domain also has DNA and RNA binding activity.^{103,174} Four of the five epitopes detected in SLE and autoimmune hepatitis were in the coiled-coil domain.¹⁷⁵ The affinity between the TPR and coiled-coil domain is high.¹⁷⁶ The target binding affinity of the TPR domain is strong and equivalent to antibodies.¹⁰³ Hayashida et al. detected the bait protein and Eri15 in a combined molecular weight band by conventional Western blotting using SDS, DTT, and heat treatment of immunoprecipitated proteins from the recombinant Spag1-1 specific region and mouse ovarian lysates. It was suggested that Spag1 shows a robust affinity depending on the partner molecule.¹⁵⁸ HSP does not have a repeat domain and captures the substrate proteins by closing the lid using ATP energy, and protein/HSP complexes released from dead cells are captured by HSP receptors on DC.^{177,178} Similarly, endogenous proteins with a strong affinity for Spag1-2 may be released outside the cell as endogenous antigen/Spag1-2 complex.

Production of autoantibody As mentioned above, SPAG1-1, which was found as one of the target antigens of ASA in infertile males, has high immunogenicity, but its epitope is unknown. Human SPAG1-1 shares 365 aa on the N-terminal with SPAG1-2 and has a SPAG1-1 specific sequence of 51 aa at the C-terminal, but the homology of the specific sequence and common part is low.¹⁶⁰ It is difficult to think that the epitope of anti-SPAG1 antibody exists in SPAG1-2, a housekeeping protein, so the epitope likely exists in the SPAG1-1 specific sequence. Antibodies may not usually be produced against SPAG1-1, a sequestered antigen expressed in immune-privileged stem cells and testis.¹⁶⁰ However, in females, antibodies will be produced due to exposure to the immune system by sperm. Unlike anti-H-Y antibodies that affect the maintenance of pregnancy, antibodies against SPAG1-1 on sperm, which are not formed in the fetus, are considered to have sufficient function as an antibody. Among the many proteins or protein complexes released from male Soc that have necrosis due to the influx of SPAG1-1 protein by the exosome, the anti-SPAG1-1 antibody produced by SPAG1-1 specific LLMPC (SPAG1-1-LLMPC) binds to SPAG1-1 of the autoantigen A/SPAG1-2/SPAG1-1 complex. This immune complex is phagocytosed by DC via the FcγR and is presented by HLA class II or HLA class I by cross-presentation. Autoantigen A-specific B cells capture and internalize the autoantigen A/SPAG1-2/SPAG1-1/anti-SPAG1-1 antibody complex with BCR or FcγR and present the antigen with HLA class II molecules (Autoantigen A and SPAG1-2 are not antigen-antibody bindings, so the autoantigen A epitope is empty). Usually, when DC presents a complex with only autoantigen A through priming, autoantigen A-specific naive CD4⁺T cells are not activated by autoantigen A-specific Tregs, and autoantibodies are not produced. As mentioned above, this possibility is low because AID with autoantibody developed after BMT, where Treg is increasing.⁸³ Based on the observation that many autoantigen epitopes were located in the coiled-coil region,¹⁷⁹ the epitopes of the autoantigens may be cryptic and not recognized by Treg. However, it is difficult that all epitopes of many autoantigens are assumed to be cryptic. It has been observed that misfolded proteins are presented in HLA class II molecules.⁸⁴ The binding between SPAG1-2 and SPAG1-1 is a strong affinity between TPR domains, and in the case of SPAG1-2 and a client protein with strong affinity, it may be primed as a complex peptide (or protein) in APC and presented on the HLA class II molecule. SPAG1-1 specific naive CD4⁺T cells recognize SPAG1-1 epitope and are activated by DC presenting a complex peptide containing two epitopes of autoantigen A and SPAG1-1 (Unlike endogenous antigens such as autoantigen A and SPAG1-2, SPAG1-1 is an sequestered protein and is usually not suppressed by Treg). SPAG1-1 specific effector CD4⁺T cells bind to the complex peptide SPAG1-1 epitope presented by autoantigen A-specific B cells, which activates B cells to produce autoantibody A (i.e., helper T cell bypass). Since SPAG1-2 as a chaperone forms a complex with many autoantigens, many autoantibodies are produced (similar to epitope spreading?).¹⁸⁰ After necrosis of target cells, the released SPAG1-1 stimulates SPAG1-1-LLMPCs to maintain antibody production and new SPAG1-1-LLMPCs will also be differentiated. The above autoantibody production is not due to immune abnormalities but is an extension of the normal immune response.

Chaperones that capture many autoantigens include not only HSP, SPAG1, and P1H1D1/2 but also RPAP3 and DNAAF2, which are members of R2SP-like co-chaperone complexes such as

R2TP and R2SD.¹⁶¹ It is unknown whether PIH1D1/2, RPAP3, and DNAAF2 have an isoform also expressed in sperm like SPAG1, induce antibody production, and can uptake client protein into DC via antibodies. HSP can be uptaken by HSP receptors of APC without antibodies.¹⁷⁸ However, ADP is easily dissociated in the priming process, and the lip opens, and it will not be presented as an autoantigen A/HSP complex. Smith et al. detected 506 client proteins by immunoprecipitation of human bronchial epithelial cell lysates with SPAG1-2 antibody.¹⁸¹ Among them, four autoantigen genes (*SSB*, *TRIM21*, *SNRPD2*, *VIM*)² are recognized, but it will be necessary to search with various tissue cells hereafter. Among the many endogenous proteins that are clients of SPAG1-2, those with an extreme affinity with SPAG1-2 may become autoantigens. In addition, the tissue-specific proteins, which account for 80% of the autoantigens,² are thought to have evolved into more advanced protein complexes to perform tissue-specific functions compared to the primitive housekeeping proteins. It has been reported that tissue-specific combination formation of transcriptional coregulator complexes is essential for tissue-specific transcriptional regulation.¹⁸² R2SP complex also has the R2TP complex and R2SD complex, which share some of their constituent proteins. The evolution and diversity of protein complexes under limited genes leads to tissue-specific responses, and chaperone, which supports the quaternary structure, is thought to have coevolved as a complex. HSP, which is evolutionarily well conserved from single-celled organisms and is ubiquitous in all tissues,¹⁷⁸ has poor substrate protein selectivity¹⁸³ and cannot explain the selectivity of tissue-specific proteins in AID.

The individual is likely sensitized by both SPAG1-1 and H-Y Ag by sperm. Sperm appears unique because they can present SPAG1-1 and H-Y Ag to females as antigens and transmit acquired immunity to offspring with chimeric LLMPC through pregnancy. Furthermore, SPAG1-1 differs from other SPAG proteins in that it is not only immunogenic because it is expressed in immune-privileged testis and stem cells, but it is also incorporated into the mitochondrial outer membrane to induce necrosis, and the antibody binds to SPAG1-2 bound to many autoantigens to promote the production of autoantibodies. The SPAG1 protein is a unique molecule in that the initiation and persistence of inflammation in AIDs and the production of autoantibodies are inseparable. As mentioned above, the SPAG1 gene has been detected in new disease susceptibility tests such as GWAS and EWAS in RA, GO, and SSc, but no reports show the relationship between H-Y Ag genes and AIDs. Females do not have H-Y Ag genes, and male Mc cells resulting from male pregnancy are few in the blood, so they will not affect polymorphism detection. In males, the maternal chimeric H-Y-LLMPC mainly acts as effector cells, so the polymorphism of the individual's H-Y Ag genes does not seem to be involved in disease susceptibility.

Gender bias of cancer susceptibility and lifespan

In many cancers, the incidence rate of females is lower than that of males, and there is also gender bias, but the cause is unclear.¹⁸⁴ In thyroid cancer, Mc cells are less in the blood and increase in cancer tissue, and Mc cells with hematopoietic differentiation may destroy tumors. There are many reports that Mc is suppressive against cancer.¹⁸⁵ In leukemia patients, F→M HSCT has a higher graft-versus-leukemia effect independent of GVHD development than other combinations, suggesting the involvement of H-Y Ag.¹² As mentioned above, Spag1-1 and Spag1-2 are expressed in both stem cells and cancer cells (cancer stem cells?), suggesting their involvement in the Warburg effect by mitochondrial quantity control.¹⁶⁰ If malignant transformation occurs in stem cells, including mesenchymal stem cells (MSC), chimeric male MSC will also become malignant with the same probability as own stem cells. There is also a report that MSC transplantation in patients with hematologic malignancies increases recurrence,⁷⁴ suggesting that MSC may be involved not only in its malignant transformation but also in cancer repair. mHA is also expressed on tumor cells.¹⁸⁶ If the individual has female H-Y-LLMPC, necrosis due to self-destruction of cancer cells will cause LLMPC to migrate, and H-Y Ag-expressing cancer cells will cause necrosis by the SPAG1-1/H-Y-LLMPC/exosome axis. In this case, females have not only chimeric H-Y-LLMPC from their mother but also their own H-Y-LLMPC through sperm sensitization after puberty, whereas males have only chimeric H-Y-LLMPCs from their mother. In addition, in males, all the cells surrounding the cancer express the H-Y antigen, so the SPAG1-1/H-Y-LLMPC/exosome axis effect will be diluted. For this reason, the incidence of cancer in females will be relatively lower than in males. Generally, females tend to have a longer lifespan than males,¹⁸⁷ which may be affected by the difference in cancer incidence due to SPAG1-1/H-Y-LLMPC/exosome axis. Furthermore, in the acquisition of chimeric MSC, males only acquire aged maternal chimeric MSC from their mother, whereas females can acquire young, highly regenerative fetal chimeric MSC through pregnancy. Regardless of the onset of cancer, microchimerism may also affect the gender bias of life span in terms of tissue repair ability.

Gonad dysgenesis and Xt-mir

Three out of eight Xt-mir targeting mouse Spag1-2 mRNA 3'UTR are also expressed in the ovary.¹⁸⁸ These Xt-mir are likely contained in exosomes released from testes and ovaries. The increase in AIDs in Turner's syndrome,³⁶ POI,⁴² and Klinefelter's syndrome³⁴ mentioned above may be due to

decreased release of Xt-mir-containing exosomes and inability to suppress Eri15/SPAG1 axis by common gonadal development disorders.

Autoantibody and prevalence

In this simulation, by seeking the optimal combination of LLBMC and Soc in an allogeneic relationship, it was finally pointed out that autoantibodies may not be directly involved in developing AIDs. This result is consistent with the fact that autoantibody production is not essential for AIDs. The only thing that was difficult to explain in the simulation was the existence of adult male-dominant AIDs. Most of the middle-aged and elderly male-dominant AIDs have a low prevalence (Fig. 1). AIDs with a high prevalence of more than 10 per 100,000 population were 21 (47%) of 45 AIDs with pathogenic molecular target, while 7 (26%) of 27 AIDs without pathogenic molecular target. However, not all AIDs with pathogenic molecular targets have a high prevalence (Fig. 1). That is, the presence of autoantibodies is a necessary condition for an increase in the prevalence of AIDs, but it is not a sufficient condition, and factors other than the mere presence or absence of autoantibodies are presumed to be involved. For example, the prevalence of triggering infections may be affected. Acquisition of autoantibodies may be determined by the strength of autoantigen and SPAG1-2 affinities, and autoantibody hazards may be determined by the affinities with binding autoantigens, the sites of autoantigen expression in cells, and the functions involved. The degree of pathologic modification by autoantibodies may affect the rate of consultation at medical institutions and the rate of diagnosis, which may be reflected in the difference in prevalence. Mc is such a common event, and Mc cells are observed even in asymptomatic healthy females, so it is thought that it cannot be considered a cause of cGVHD and AIDs.¹⁸⁹ However, various individual factors other than those mentioned above are involved in the pathway from Mc to the onset of AIDs. Ultimately, the ratio of male MSC, female H-Y-LLMPC, and female SPAG1-1-LLMPC in the bone marrow will decide the onset of AIDs.

The fact that adult male-dominant AIDs and AIDs without well-defined autoantigens show a low prevalence may be explained by the presence or absence of pathogenic autoantibodies. A female-dominant chronic inflammatory group develops in the adult population where the Eri15/SPAG1/H-Y-LLMPC/male MSC axis is working by the same trigger in the same organ. Acquisition of chimeric female SPAG1-1-LLMPC in this population would be the same in both males and females because they are maternally derived. Males without chimeric female SPAG1-1-LLMPC do not produce autoantibodies. Females without chimeric female SPAG1-1-LLMPC are divided into those who produce autoantibodies and those who do not, depending on the presence or absence of their own SPAG1-1-LLMPC acquired by sperm sensitization after puberty. As a result, the rate of females in the group without autoantibodies will not be overwhelmingly higher than in the group with autoantibodies. If the autoantibodies were not pathogenic, they would all show the same phenotype and be diagnosed with the same disease, and the antibody retention rate in males would be lower than in females. If autoantibodies are pathogenic (although cytotoxic T cells may also be involved), the phenotypes of autoantibody-possession and non-possession patients will be completely different so that will be recognized as different disease groups. Moreover, it is predicted that the prevalence rate and female/male ratio of autoantibody-non-possession groups are lower than that of autoantibody-possession groups. Sjogren's syndrome (SjS) and Mikulicz's disease (MD), Hashimoto's disease (HD) and Riedel's thyroiditis (RT), RA and adult Still's disease (ASD), SLE and discoid lupus erythematosus (DLE), and SSc and CREST syndrome (CREST) are possible AIDs suggestive of the above two related groups. These disease pairs are close to the onset age, with the latter tends to be higher (Fig. 1). The apoptosis image by autoimmune response is expected to be detected in the tissues of the autoantibody-possession group but is rarely observed in the autoantibody-non-possession group. In fact, there are reports that apoptosis is significantly less in MD tissues than in SjS.^{190,191} MD and RT are classified as IgG4-RD. IgG4-RD is characterized by compression symptoms due to fibrosis and the accumulation of IgG4-holding plasma cells. It is a chronic inflammatory disease common in middle-aged and older adults and responds well to steroid and B cell depletion therapy but does not have defined autoantibodies.¹⁹² IgG4 is thought to have an anti-inflammatory effect and is produced as a response to inflammatory stimuli.¹⁹³ Due to the absence of pathogenic autoantibodies, the disease activity is weak and the onset of subjective symptoms is delayed. It may develop in middle-aged and older adults who cause compression symptoms due to the fibrosis and infiltration of reactive mature B cells as the terminal image of chronic inflammation. The reason why the effect of steroid and B cell depletion therapy is more robust than regular AIDs is probably because they act on accumulated mature B cells rather than LLMPC and weaken compression symptoms. IgG4-RD may be looking at the terminal image of non-autoantibody-bearing AIDs without SPAG1-1-LLMPC.

Inflammatory field

In the model presented here, three types of cells, male MSC, female H-Y-LLMPC, and female SPAG1-1-LLMPC, are required to develop AIDs. As chimeric cells, males require female H-Y-LLMPC and female SPAG1-1-LLMPC, while females require male MSC. Males can use their own

H-Y antigen or SPAG1-1-sensitized male LLMPC, but chimeric male MSC is essential for females. Necrosis as a trigger is necessary to induce the migration of LLMPC to the inflammatory field, and especially for females, it is also necessary to replace male Soc with male MSC. Male MSC and female H-Y-LLMPC are required for inflammation persistence, and SPAG1-1-LLMPC is required for autoantibody production. If the autoantibodies produced are self-reactive, they will be accompanied by apoptosis or dysfunction of target cells. However, they are an incidental reaction and may not necessarily be required to maintain the inflammatory field. As long as the relationship between male Soc and female H-Y-LLMPC continues, even without autoimmune reactions caused by pathogenic autoantibodies, necrosis→release of inflammatory cytokines and chemokines by phagocytic cells that have taken up damage-associated molecular patterns (DAMPs)→LLMPC and MSC migration→regeneration by MSC, supply of Spag1-1 protein by H-Y-LLMPC→necrosis cycle, and the inflammatory field will be established and sustained. The group mentioned above in which autoantibodies appear after acetaminophen liver injury or after vasectomy but do not develop AIDs corresponding to antibodies can be explained by the presence of necrosis and SPAG1-1-LLMPC but the absence of H-Y-LLMPC. AMA in post-acetaminophen liver injury was transient, and there was no gender bias in its detection rate,⁴⁵ supporting the absence of chimeric H-Y-LLMPC. This phenomenon may be related to the high use of acetaminophen leads to plasma cell disorders.¹⁹⁴ Furthermore, it also means no gender bias in the autoantibody production system. Post-vasectomy males who develop autoantibodies and ASA do not develop AIDs⁹⁹ but often present with infertility after vasovasostomy.¹¹¹ ASA is considered a pathogenic antibody, but H-Y Ag is not included in SPAG detected by seminal plasma of ASA-positive infertile males.¹⁰⁹ For males, SPAG is a sequestered antigen, and antibodies are produced, whereas H-Y Ag is an autoantigen and does not produce antibodies, thus not being included in SSA. These facts indicate that it is SSA that does not contain H-Y Ag, namely SPAG, that induces autoantibody production in males after vasectomy and that only autoantibodies without H-Y Ab do not cause AIDs. NMDAR encephalitis with ovarian teratoma seems to be an AID with pathogenic autoantibodies, but it may not involve H-Y-LLMPC or SPAG1-1-LLMPC. Since neurons rarely express HLA class I molecules,⁹² they do not present receptor antigens or H-Y antigens. Therefore, the receptor antigen released by necrosis of teratoma is treated as an exogenous antigen for APC, so anti-receptor antibodies are not autoantibodies, and SPAG1-1-LLMPC is not required. Also, even if H-Y-LLMPC exists, it cannot act on neurons, so the chain of necrosis will not occur. These predictions are supported by encephalitis being cured by removing teratoma. In addition, if the anti-receptor-specific LLMPC continuously releases anti-receptor antibodies, the encephalitis will persist, but this does not occur,¹²⁹ suggesting that sustained antigen stimulation may be necessary for the antibody production of LLMPC in vivo. Therefore, NMDAR encephalitis is not strictly AIDs in this model.

De Bari suggests that the effect of molecular-targeted treatment for cytokines, B cells, and osteoclasts in RA is limited, and bone destruction progresses even if the inflammatory findings are in remission, so the suppression of inflammation is not enough to stop the progression of RA, and the mechanism of joint destruction may be detached from inflammation.¹⁹⁵ Immunosuppressive agents, molecular-targeted drugs, and MSC transplantation therapy for AIDs show a certain level of alleviation. However, they are not curative treatments because they act only on the inflammation reaction associated with necrosis and autoimmune reaction due to autoantibodies, but not on the necrosis of male Soc caused by H-Y-LLMPC. It is predicted that if chimeric male MSC in females and chimeric female H-Y-LLMPC in males can be depleted, the chain reaction in the inflammatory field can be broken.

The origin of AIDs

Mammals that enable placental nurture face the problem of microchimerism. Male β cell substitution has been observed in the female pancreas,⁷⁰ but there is no problem if Mc cells are compatible Soc between males and females. However, male-female replacement of sex hormone-producing cells results in the production of endocrine disruptors. Therefore, exosomes targeting the H-Y antigen may eliminate male cells using the Eri15/SPAG1 axis. Female Soc cannot be excluded because it does not have a molecule that recognizes it. However, this system is thought to be immune to selection pressure because females should be protected for the survival of organisms, especially mammals. The reason why six genes that provide the H-Y antigen remain on the Y chromosome maybe because it is beneficial for females to identify male cells. Then, why not directly use H-Y antigen-specific T and B cells for elimination? When the mother becomes pregnant with a male fetus, the direct reaction is thought to be severely suppressed by the maternal H-Y antigen-specific Treg and anti-H-Y antigen idiotype antibodies so as not to reject the male fetus. Male Mc cells that invade the thymus may activate H-Y Ag-specific Treg, or induced Treg may be generated by contact with H-Y Ag at the periphery. H-Y-LLMPC, generated after escaping a strict immune surveillance system, had to eliminate male Mc cells by harboring spag1-1 protein in immune-privileged exosomes, which seems purposeful. The subsequent autoimmune reaction is considered to be a secondary reaction caused by the fact that the female is presented as an exogenous antigen by the sperm and acquires antibodies because SPAG1-1 is an immune-privileged

molecule, and its isoform protein (SPAG1-2) was a chaperone involved in the formation of many protein complexes in somatic cells. Clinical concordance for SSc in monozygotic twins was <5%¹⁶⁴. Monozygotic twins, whose Mc environment is considered to be almost the same, have few simultaneous onset, so postnatal trigger or sperm sensitization may have a significant effect. In recent years, AIDs has tended to increase, and changes in environmental factors, including the intestinal flora, are thought to be the cause,^{39,196} but from the author's hypothesis, it is speculated that the increase in opportunities for sensitization by sperm antigens in females may be the cause. As placental mammals with internal fertilizing, humans cannot avoid ASA and Mc and may be destined to develop AIDs.

CONCLUSION

Assuming that cGVHD and AIDs are caused by microchimerism, the author simulated which gender combination of LLBMC and Soc in the allogeneic relationship matches the gender bias and incidence rate. As a result, it was reasonable to assume that female LLBMC is attacking male Soc. In order to elucidate the further missing link connecting AIDs and microchimerism, the author proposed the following hypotheses. After puberty, females acquire H-Y-LLMPC and SPAG1-1-LLMPC by sperm or male pregnancy. During pregnancy, female H-Y-LLMPC, female SPAG1-1-LLMPC, and male MSC are transferred and settled as microchimerism cells from the mother in males and from the mother and older brother through the mother in females. Immune cells such as LLMPC and MSC migrate due to necrosis caused by triggers such as infectious diseases. In females, female Soc that has been eliminated is regenerated by male MSC and replaced with male Soc. Spag1-1 protein-encapsulated exosomes with H-Y-BCR on the surface are released from female H-Y-LLMPC. This exosome is taken up by male Soc presenting H-Y Ag on HLA class I molecules, Spag1-1 protein is integrated into the mitochondrial outer membrane, and at the same time, it binds to autoantigen A/Spag1-2 complex. Eri15 is transported by SPAG1-2 and incorporated into the matrix via Spag1-1 on the mitochondrial outer membrane, destroying mtDNA and causing mitophagy. Cells with excessive mitophagy undergo necrosis from mitoptosis and release cell contents. The anti-Spag1-1 antibody secreted from SPAG1-1-LLMPC binds to the autoantigen A/Spag1-2/SPAG1-1 complex in these. This IC is taken up by FcγR on DC, primed and presented with the HLA classII molecule as a complex peptide. The SPAG1-1 specific naive CD4⁺T cell reacting to the SPAG1-1 epitope of the complex peptide is activated. Autoantigen A-specific B cell takes up IC by BCR or FcγR, presents complex peptide with HLA class II molecule, and is activated by SPAG1-1-specific effector CD4⁺T cell bound to the SPAG1-1 epitope of the complex peptide to produce anti-A antibody. Among these antibodies, those that bind to autoantigens and impair cell function or cause apoptosis become pathogenic autoantibodies and modify the pathology. Mitoptosis by Eri15/SPAG1-2/SPAG1-1 axis and apoptosis by pathogenic autoantibodies promote the migration of MSC and immune cells, including LLMPC, to form an inflammatory field.

REFERENCES

1. Hashimoto H. Zur Kenntniss der lymphomatösen Veränderung der schilddrüse (struma lymphomatosa). *arch Klin Chir* 1912;97:219-48.
2. Hayter SM, Cook MC. Updated assessment of the prevalence, spectrum and case definition of autoimmune disease. *Autoimmunity reviews* 2012;11:754-65.
3. Herrero-Cervera A, Soehnlein O, Kenne E. Neutrophils in chronic inflammatory diseases. *Cellular & Molecular Immunology* 2022;19:177-91.
4. Parikh-Patel A, Gold E, Utts J, Gershwin ME. The association between gravidity and primary biliary cirrhosis. *Annals of epidemiology* 2002;12:264-72.
5. Stagnaro-Green A. Postpartum thyroiditis. *Best Practice & Research Clinical Endocrinology & Metabolism* 2004;18:303-16.
6. Nelson JL, Furst DE, Maloney S, et al. Microchimerism and HLA-compatible relationships of pregnancy in scleroderma. *The Lancet* 1998;351:559-62.
7. Bianchi DW, Zickwolf GK, Weil GJ, Sylvester S, DeMaria MA. Male fetal progenitor cells persist in maternal blood for as long as 27 years postpartum. *Proceedings of the National Academy of Sciences* 1996;93:705-08.
8. Shrivastava S, Naik R, Suryawanshi H, Gupta N. Microchimerism: A new concept. *Journal of oral and maxillofacial pathology: JOMFP* 2019;23:311.
9. Nelson JL. The otherness of self: microchimerism in health and disease. *Trends in immunology* 2012;33:421-7.
10. Murray J, Stringer J, Hutt D. Graft-versus-host disease (GvHD). *The European blood and marrow transplantation textbook for nurses: Under the auspices of EBMT* 2018;221-51.
11. Remberger M, Kumlien G, Aschan J, et al. Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. *Biology of blood and*

marrow transplantation 2002;8: 674-82.

12. Randolph SS, Gooley TA, Warren EH, Appelbaum FR, Riddell SR. Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. *Blood* 2004;103:347-52.

13. Kim HT, Zhang MJ, Woolfrey AE, et al. Donor and recipient sex in allogeneic stem cell transplantation: what really matters. *Haematologica* 2016;101:1260.

14. Morrison SJ, Scadden, DT. The bone marrow niche for haematopoietic stem cells. *Nature* 2014;505:327-34.

15. Khodadadi L, Cheng Q, Radbruch A, Hiepe, F. The maintenance of memory plasma cells. *Frontiers in immunology* 2019;721.

16. Mahmood U, O'Donoghue K. Microchimeric fetal cells play a role in maternal wound healing after pregnancy. *Chimerism* 2014;5:40-52.

17. Pritz T, Lair J, Ban M, et al. Plasma cell numbers decrease in bone marrow of old patients. *European journal of immunology* 2015;45:738-46.

18. Gahrton G, Iacobelli S, Apperley J, et al. The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma: reduced relapse risk in female to male transplants. *Bone marrow transplantation* 2005;35:609-17.

19. Loren AW, Bunin GR, Boudreau C, et al. Impact of donor and recipient sex and parity on outcomes of HLA-identical sibling allogeneic hematopoietic stem cell transplantation. *Biology of Blood and Marrow Transplantation* 2006;12:758-69.

20. Kollman C, Howe CW, Anasetti C, et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. *Blood, The Journal of the American Society of Hematology* 2001;98:2043-51.

21. Inoue D, Yoshida K, Yoneda N, et al. IgG4-related disease: dataset of 235 consecutive patients. *Medicine* 2015;94.

22. Friedrich P, Guerra-García P, Stetson A, Duncan C, Lehmann L. Young female donors do not increase the risk of graft-versus-host disease or impact overall outcomes in pediatric HLA-matched sibling hematopoietic stem cell transplantation. *Biology of Blood and Marrow Transplantation* 2018;24:96-102.

23. Zhang H. Impact of donor and recipient characteristics on graft-versus-host disease and survival in HLA-matched sibling hematopoietic stem cell transplantation. *Transfusion and Apheresis Science* 2020;59:102743.

24. Jacobsohn DA, Vogelsang GB. Acute graft versus host disease. *Orphanet journal of rare diseases* 2007;2:1-9.

25. Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy. *Nature reviews immunology* 2012;12:443-58.

26. Coassin NA, Kline DL. Radiophosphorus measurement of the lifespan of lymphocytes in the rabbit. *American Journal of Physiology-Legacy Content* 1957;190:147-51.

27. Vigorito AC, Campregher PV, Storer BE, et al. Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. *Blood, The Journal of the American Society of Hematology* 2009;114:702-8.

28. Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report. *Biology of Blood and Marrow Transplantation*, 2015;21:389-401.

29. Pavletic SZ, Carter SL, Kernan NA, et al. Unrelated Donor Marrow Transplantation Trial. Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation. *Blood* 2005;106:3308-13.

30. Kuzmina Z, Gounden V, Curtis L, et al. Clinical significance of autoantibodies in a large cohort of patients with chronic graft-versus-host disease defined by NIH criteria. *American journal of hematology* 2015;90:114-9.

31. Yanir AD, Hanson IC, Shearer WT, et al. High incidence of autoimmune disease after hematopoietic stem cell transplantation for chronic granulomatous disease. *Biology of Blood and Marrow Transplantation* 2018;24:1643-50.

32. Gravholt CH, Viuff MH, Brun S, Stochholm K, Andersen NH. Turner syndrome: mechanisms and management. *Nature Reviews Endocrinology* 2019;15:601-14.

33. Groth KA, Skakkebaek A, Høst C, Gravholt CH, Bojesen A. Klinefelter syndrome—a clinical update. *The Journal of Clinical Endocrinology & Metabolism* 2013;98:20-30.

34. Seminog OO, Seminog AB, Yeates D, Goldacre MJ. Associations between Klinefelter's syndrome and autoimmune diseases: English national record linkage studies. *Autoimmunity* 2015;48:125-8.

35. Scofield RH, Bruner GR, Namjou B, et al. Klinefelter's syndrome (47, XXY) in male systemic lupus erythematosus patients: support for the notion of a gene-dose effect from the X chromosome. *Arthritis & Rheumatism: Official Journal of the American College of Rheumatology* 2008;58:2511-7.

36. Jørgensen KT, Rostgaard K, Bache I, et al. Autoimmune diseases in women with Turner's

syndrome. *Arthritis & Rheumatism* 2010;62:658-66.

37. Navarro-Cobos MJ, Balaton BP, Brown CJ. Genes that escape from X-chromosome inactivation: Potential contributors to Klinefelter syndrome. In *American Journal of Medical Genetics Part C: Seminars in Medical Genetics* Hoboken, USA: John Wiley & Sons, Inc. 2020, June;184:226-238.
38. Ngo ST, Steyn FJ, McCombe PA. Gender differences in autoimmune disease. *Frontiers in neuroendocrinology* 2014;35:347-69.
39. Markle JG, Frank DN, Mortin-Toth S, et al. Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity. *Science* 2013;339:1084-8.
40. Fitzpatrick F, Lepault F, Homo-Delarche F, Bach JF, Dardenne M. Influence of castration, alone or combined with thymectomy, on the development of diabetes in the nonobese diabetic mouse. *Endocrinology* 1991;129:1382-90.
41. Kirshenbaum M, Orvieto R. Premature ovarian insufficiency (POI) and autoimmunity-an update appraisal. *Journal of assisted reproduction and genetics* 2019;36:2207-15.
42. Grossmann B, Saur S, Rall K, et al. Prevalence of autoimmune disease in women with premature ovarian failure. *The European Journal of Contraception & Reproductive Health Care* 2019;25:72-75.
43. Wraith DC, Goldman M, Lambert PH. Vaccination and autoimmune disease: what is the evidence?. *The Lancet* 2003;362:1659-66.
44. Nche EN, Amer R. Lens-induced uveitis: an update. *Graefe's Archive for Clinical and Experimental Ophthalmology* 2020;258:1359-65.
45. Leung PS, Rossaro L, Davis PA, et al. Antimitochondrial antibodies in acute liver failure: implications for primary biliary cirrhosis. *Hepatology* 2007;46:1436-42.
46. Arnaiz SL, Llesuy S, Cutrín JC, Boveris A. Oxidative stress by acute acetaminophen administration in mouse liver. *Free Radical Biology and Medicine* 1995;19:303-10.
47. Sener AG, Afsar I. Infection and autoimmune disease. *Rheumatology international* 2012;32:3331-8.
48. Magna M, Pisetsky DS. The role of cell death in the pathogenesis of SLE: is pyroptosis the missing link?. *Scandinavian journal of immunology* 2015;82:218-24.
49. Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. *science* 2004;303:1532-5.
50. Darrah E, Andrade F. NETs: the missing link between cell death and systemic autoimmune diseases?. *Frontiers in immunology* 2013;3:428.
51. Pender MP. Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases. *Trends in immunology* 2003;24:584-8.
52. Bernin H, Lotter H. Sex bias in the outcome of human tropical infectious diseases: influence of steroid hormones. *The Journal of infectious diseases* 2014;209:S107-S113.
53. Fink SL, Cookson BT. Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells. *Infection and immunity* 2005;73:1907-16.
54. Dobson R, Giovannoni G. Multiple sclerosis—a review. *European journal of neurology* 2019;26:27-40.
55. Hughes RA, Cornblath DR. Guillain-barre syndrome. *The Lancet* 2005;366:1653-66.
56. Tenembaum S, Chitnis T, Ness J, Hahn JS. Acute disseminated encephalomyelitis. *Neurology* 2007;68:S23-S36.
57. Dubey D, Pittcock SJ, Kelly CR, et al. Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. *Annals of neurology* 2018;83:166-77.
58. Anderson NE, Barber PA. Limbic encephalitis—a review. *Journal of Clinical Neuroscience* 2008;15:961-71.
59. McKenna WJ, Maron BJ, Thiene G. Classification, epidemiology, and global burden of cardiomyopathies. *Circulation research* 2017;121:722-30.
60. Bracamonte-Baran W, Čiháková D. Cardiac autoimmunity: myocarditis. *The Immunology of Cardiovascular Homeostasis and Pathology* 2017:187-221.
61. Brambatti M, Matassini MV, Adler ED, Klingel K, Camici PG, Ammirati E. Eosinophilic myocarditis: characteristics, treatment, and outcomes. *Journal of the American College of Cardiology* 2017;70:2363-75.
62. Cooper Jr LT. Myocarditis. *New England Journal of Medicine* 2009;360:1526-38.
63. Ransohoff RM, Engelhardt B. The anatomical and cellular basis of immune surveillance in the central nervous system. *Nature Reviews Immunology* 2012;12:623-35.
64. Franklin RJ, Ffrench-Constant C. Regenerating CNS myelin—from mechanisms to experimental medicines. *Nature Reviews Neuroscience* 2017;18:753-69.
65. Mahar M, Cavalli V. Intrinsic mechanisms of neuronal axon regeneration. *Nature Reviews Neuroscience* 2018;19:323-37.
66. Uygur A, Lee RT. Mechanisms of cardiac regeneration. *Developmental cell* 2016;36:362-74.
67. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. *Blood* 2005;105:1815-22.

68. Fu X, Liu G, Halim A, Ju Y, Luo Q, Song AG. Mesenchymal stem cell migration and tissue repair. *Cells* 2019;8:784.
69. Li, M., & Ikehara, S. Bone-marrow-derived mesenchymal stem cells for organ repair. *Stem cells international*, 2013.
70. Nelson JL, Gillespie KM, Lambert NC, et al. Maternal microchimerism in peripheral blood in type 1 diabetes and pancreatic islet β cell microchimerism. *Proceedings of the National Academy of Sciences* 2007;104:1637-42.
71. Tanaka K, Ogino R, Yamakawa S, Suda S, Hayashida K. Role and function of mesenchymal stem cells on fibroblast in cutaneous wound healing. *Biomedicines* 2022;10:1391.
72. Usategui A, Del Rey MJ, Pablos JL. Fibroblast abnormalities in the pathogenesis of systemic sclerosis. *Expert Review of Clinical Immunology* 2011;7:491-8.
73. Lee HY, Hong IS. Double-edged sword of mesenchymal stem cells: cancer-promoting versus therapeutic potential. *Cancer science* 2017;108:1939-46.
74. Gao F, Chiu SM, Motan DAL, et al. Mesenchymal stem cells and immunomodulation: current status and future prospects. *Cell death & disease* 2016;7:e2062-e2062.
75. Miklos DB, Kim HT, Miller KH, et al. Antibody responses to HY minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. *Blood* 2005;105:2973-8.
76. Stern M, Brand R, De Witte T, et al. Female-versus-male alloreactivity as a model for minor histocompatibility antigens in hematopoietic stem cell transplantation. *American journal of transplantation* 2008;8:2149-57.
77. Linscheid C, Petroff MG. Minor histocompatibility antigens and the maternal immune response to the fetus during pregnancy. *American Journal of Reproductive Immunology* 2013; 69:304-14.
78. Popli R, Sahaf B, Nakasone H, Lee JYY, Miklos DB. Clinical impact of HY alloimmunity. *Immunologic research* 2014;58:249-58.
79. Nakasone H, Tian L, Sahaf B, et al. Allogeneic HY antibodies detected 3 months after female-to-male HCT predict chronic GVHD and nonrelapse mortality in humans. *Blood, The Journal of the American Society of Hematology* 2015;125:3193-201.
80. Sahaf B, Yang Y, Arai S, Herzenberg LA, Herzenberg LA, Miklos DB. H-Y antigen-binding B cells develop in male recipients of female hematopoietic cells and associate with chronic graft vs. host disease. *Proceedings of the National Academy of Sciences* 2013;110:3005-10.
81. Gallardo D, Aróstegui JI, Balas A, et al. Disparity for the minor histocompatibility antigen HA-1 is associated with an increased risk of acute graft-versus-host disease (GvHD) but it does not affect chronic GvHD incidence, disease-free survival or overall survival after allogeneic human leucocyte antigen-identical sibling donor transplantation. *British Journal of Haematology* 2001;114:931-6.
82. Grumet FC, Hiraki DD, Brown BW, et al. CD31 mismatching affects marrow transplantation outcome. *Biology of Blood and Marrow Transplantation* 2001;7:503-12.
83. Seissler N, Schmitt E, Hug F, et al. Methylprednisolone treatment increases the proportion of the highly suppressive HLA-DR⁺-Treg-cells in transplanted patients. *Transplant immunology* 2012;27:157-61.
84. Jin H, Arase N, Hirayasu K, et al. Autoantibodies to IgG/HLA class II complexes are associated with rheumatoid arthritis susceptibility. *Proceedings of the National Academy of Sciences* 2014;111:3787-92.
85. Hiepe F, Dörner T, Hauser AE, Hoyer BF, Mei H, Radbruch A. Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. *Nature Reviews Rheumatology* 2011;7:170-8.
86. Lambert NC, Erickson TD, Yan Z, et al. Quantification of maternal microchimerism by HLA-specific real-time polymerase chain reaction: studies of healthy women and women with scleroderma. *Arthritis & Rheumatism* 2004;50:906-14.
87. Berger M, Biasin E, Saglio F, Fagioli F. Innovative approaches to treat steroid-resistant or steroid refractory GVHD. *Bone marrow transplantation* 2008;42:S101-S105.
88. Wang L, Wang FS, Gershwin ME. Human autoimmune diseases: a comprehensive update. *Journal of internal medicine* 2015;278:369-95.
89. Cutler C, Miklos D, Kim HT, et al. Rituximab for steroid-refractory chronic graft-versus-host disease. *Blood* 2006;108:756-62.
90. Tony HP, Burmester G, Schulze-Koops H, et al. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). *Arthritis research & therapy* 2011;13:1-14.
91. DiLillo DJ, Hamaguchi Y, Ueda Y, et al. Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. *The Journal of Immunology* 2008;180:361-71.
92. Ichiryu N, Fairchild PJ. Immune privilege of stem cells. *Embryonic Stem Cell Immunobiology: Methods and Protocols* 2013;1-16.
93. Lissauer D, Piper K, Goodyear O, Kilby MD, Moss PA. Fetal-specific CD8⁺ cytotoxic T cell responses develop during normal human pregnancy and exhibit broad functional capacity. *The*

- Journal of Immunology 2012;189:1072-80.
94. Nielsen HS, Wu F, Aghai Z, et al. HY antibody titers are increased in unexplained secondary recurrent miscarriage patients and associated with low male: female ratio in subsequent live births. *Human Reproduction* 2010;25:2745-52.
 95. Petroff MG. Immune interactions at the maternal–fetal interface. *Journal of reproductive immunology* 2005;68:1-13.
 96. Kahn DA, Baltimore D. Pregnancy induces a fetal antigen-specific maternal T regulatory cell response that contributes to tolerance. *Proceedings of the National Academy of Sciences* 2010;107:9299-304.
 97. Naz RK, Menge AC. Antisperm antibodies: origin, regulation, and sperm reactivity in human infertility. *Fertility and sterility* 1994;61:1001-13.
 98. Finnegan A, Ashaye S, Hamel KM. B effector cells in rheumatoid arthritis and experimental arthritis. *Autoimmunity* 2012;45:353-63.
 99. Mathews JD, Skegg DC, Vessey MP, Konice M, Holborow EJ, Guillebaud J. Weak autoantibody reactions to antigens other than sperm after vasectomy. *Br Med J* 1976;2:1359-60.
 100. Cincinelli G, Generali E, Dudam R, Ravindran V, Selmi C. Why women or why not men? sex and autoimmune diseases. *Indian Journal of rheumatology* 2018;13:44-50.
 101. Stanley P. Golgi glycosylation. *Cold Spring Harbor perspectives in biology* 2011;3:a005199.
 102. Bednarska NG, Wren BW, Willcocks SJ. The importance of the glycosylation of antimicrobial peptides: Natural and synthetic approaches. *Drug Discovery Today* 2017;22:919-26.
 103. Björklund ÅK, Ekman D, Elofsson A. Expansion of protein domain repeats. *PLoS computational biology* 2006;2:e114.
 104. Strauss HM, Keller S. Pharmacological interference with protein-protein interactions mediated by coiled-coil motifs. *Protein-Protein Interactions as New Drug Targets* 2008;461-82.
 105. Dohle GR, Smit M, Weber RFA. Androgens and male fertility. *World journal of urology* 2003;21:341-5.
 106. Rajabi F, Drake LA, Senna MM, Rezaei N. Alopecia areata: a review of disease pathogenesis. *British Journal of Dermatology* 2018;179:1033-48.
 107. Pelletier RM, Byers SW. The blood-testis barrier and Sertoli cell junctions: Structural considerations. *Microscopy research and technique* 1992;20:3-33.
 108. Wang YX, Zhu WJ, Jiang H. Sperm exposure during menses is a risk factor for developing antisperm antibody (ASA) in female. *Archives of gynecology and obstetrics* 2013;288:1145-8.
 109. Bohring C, Krause E, Habermann B, Krause W. Isolation and identification of sperm membrane antigens recognized by antisperm antibodies, and their possible role in immunological infertility disease. *Molecular human reproduction* 2001;7:113-8.
 110. Silina K, Zayakin P, Kalnina Z, et al. Sperm-associated antigens as targets for cancer immunotherapy: expression pattern and humoral immune response in cancer patients. *Journal of immunotherapy* 2011;34:28-44.
 111. Sotolongo JR. Immunological effects of vasectomy. *The Journal of Urology* 1982;127:1063-6.
 112. Chamley LW, Clarke GN. Antisperm antibodies and conception. In *Seminars in immunopathology*. Springer-Verlag 2007 June;29:169-184.
 113. Tung KS, Cooke Jr WD, McCARTY TA, Robitaille P. Human sperm antigens and antisperm antibodies. II. Age-related incidence of antisperm antibodies. *Clinical and Experimental Immunology* 1976;25:73.
 114. Lucas PL, Rose NR. Immunological consequences of vasectomy: I. Prospective study through one-year postvasectomy. *Archives of Andrology* 1978;1:249-55.
 115. Baker HG, Clarke GN, McGowan MP, Koh SH, Cauchi MN. Increased frequency of autoantibodies in men with sperm antibodies. *Fertility and sterility* 1985;43:438-41.
 116. Soares PMF, Borba EF, Bonfá E, Hallak J, Corrêa AL, Silva CAA. Gonad evaluation in male systemic lupus erythematosus. *Arthritis & Rheumatism: Official Journal of the American College of Rheumatology* 2007;56:2352-61.
 117. D’Cruz OJ, Haas Jr GG, Reichlin M. Autoantibodies to decondensed sperm nuclear deoxyribonucleic acid in patients with antisperm antibodies and systemic lupus erythematosus detected by immunofluorescence flow cytometry. *Fertility and sterility* 1994;62:834-44.
 118. Muñoz LE, Lauber K, Schiller M, Manfredi AA, Herrmann M. The role of defective clearance of apoptotic cells in systemic autoimmunity. *Nature Reviews Rheumatology* 2010;6:280-9.
 119. Pickles S, Vigie P, Youle RJ. Mitophagy and quality control mechanisms in mitochondrial maintenance. *Current Biology* 2018;28:R170-R185.
 120. Yang SK, Zhang HR, Shi SP, et al. The role of mitochondria in systemic lupus erythematosus: a glimpse of various pathogenetic mechanisms. *Current Medicinal Chemistry* 2020;27:3346-61.
 121. Wu DJ, Adamopoulos IE. Autophagy and autoimmunity. *Clinical Immunology* 2017;176:55-62.
 122. Li W, Deng R, Jing X, Chen J, Yang D, Shen J. Acteoside ameliorates experimental autoimmune encephalomyelitis through inhibiting peroxynitrite-mediated mitophagy activation. *Free Radical Biology and Medicine* 2020;146:79-91.

123. Sasaki M, Miyakoshi M, Sato Y, Nakanuma Y. Autophagy mediates the process of cellular senescence characterizing bile duct damages in primary biliary cirrhosis. *Laboratory Investigation* 2010;90:835-43.
124. Xia M, Meng G, Jiang A, et al. Mitophagy switches cell death from apoptosis to necrosis in NSCLC cells treated with oncolytic measles virus. *Oncotarget* 2014;5:3907.
125. Shah S, Wu E, Rao VK, Tarrant TK. Autoimmune lymphoproliferative syndrome: an update and review of the literature. *Current allergy and asthma reports* 2014;14:1-5.
126. Rieux-Laucat F, Fischer A, Le Deist F. Cell-death signaling and human disease. *Current opinion in immunology* 2003;15:325-31.
127. Hanayama R, Tanaka M, Miyasaka K, et al. Autoimmune disease and impaired uptake of apoptotic cells in MFG-E8-deficient mice. *Science* 2004;304:1147-50.
128. Gaipal US, Kuhn A, Sheriff A, et al. Clearance of apoptotic cells in human SLE. Apoptosis and Its Relevance to Autoimmunity 2006;9:173-87.
129. Ación P, Ación M, Ruiz-Maciá E, Martín-Estefanía C. Ovarian teratoma-associated anti-NMDAR encephalitis: a systematic review of reported cases. *Orphanet journal of rare diseases* 2014;9:1-9.
130. Kobayashi H, Choyke PL. Near-infrared photoimmunotherapy of cancer. *Accounts of chemical research* 2019;52:2332-9.
131. Sarma JV, Ward PA. The complement system. *Cell and tissue research* 2011;343:227-35.
132. Nagata S, Hanayama R, Kawane K. Autoimmunity and the clearance of dead cells. *Cell* 2010;140:619-30.
133. Takai T. Fc receptors and their role in immune regulation and autoimmunity. *Journal of clinical immunology* 2005;25:1-18.
134. Li X, Gibson AW, Kimberly RP. Human FcR polymorphism and disease. *Fc Receptors* 2014;275-302.
135. Allen LA, Aderem A. Molecular definition of distinct cytoskeletal structures involved in complement-and Fc receptor-mediated phagocytosis in macrophages. *The Journal of experimental medicine* 1996;184:627-37.
136. Bournazos S, Gupta A, Ravetch JV. The role of IgG Fc receptors in antibody-dependent enhancement. *Nature Reviews Immunology* 2020;20:633-43.
137. Tan Sardjono C, Mottram PL, Hogarth PM. The role of FcγRIIa as an inflammatory mediator in rheumatoid arthritis and systemic lupus erythematosus. *Immunology and cell biology* 2003;81:374-81.
138. Tsuchiya N, Kobayashi S, Kawasaki A, et al. Genetic background of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis: association of HLA-DRB1* 0901 with microscopic polyangiitis. *The Journal of Rheumatology* 2003;30:1534-40.
139. Bergmann AK, Grace RF, Neufeld EJ. Genetic studies in pediatric ITP: outlook, feasibility, and requirements. *Annals of hematology* 2010;89:95-103.
140. Carmona FD, Gonzalez-Gay MA, Martín J. Genetic component of giant cell arteritis. *Rheumatology* 2014;53:6-18.
141. Jones EY, Fugger L, Strominger JL, Siebold C. MHC class II proteins and disease: a structural perspective. *Nature Reviews Immunology* 2006;6:271-82.
142. Matzaraki V, Kumar V, Wijmenga C, Zernakova A. The MHC locus and genetic susceptibility to autoimmune and infectious diseases. *Genome biology* 2017;18:1-21.
143. Hanafusa T, Pujol-Borrell R, Chiovato L, et al. Aberrant expression of HLA-DR antigen on thyrocytes in Graves' disease: relevance for autoimmunity. *The Lancet* 1983;322:1111-5.
144. Amur S, Parekh A, Mummaneni P. Sex differences and genomics in autoimmune diseases. *Journal of autoimmunity* 2012;38:J254-J265.
145. Lin YJ, Wan L, Wu JY, et al. HLA-E gene polymorphism associated with susceptibility to Kawasaki disease and formation of coronary artery aneurysms. *Arthritis & Rheumatism: Official Journal of the American College of Rheumatology* 2009;60:604-10.
146. Stassen PM, Cohen-Tervaert JW, Lems SP, Hepkema BG, Kallenberg CG, Stegeman CA. HLA-DR4, DR13 (6) and the ancestral haplotype A1B8DR3 are associated with ANCA-associated vasculitis and Wegener's granulomatosis. *Rheumatology* 2009;48:622-5.
147. Terao C, Yoshifuji H, Mimori T. Recent advances in Takayasu arteritis. *International journal of rheumatic diseases*, 2014;17:238-47.
148. Blum S, Ji Y, Pennisi D, et al. Genome-wide association study in Guillain-Barre syndrome. *Journal of Neuroimmunology* 2018;323:109-14.
149. Pawelec G. Age and immunity: what is "immunosenescence"? *Experimental gerontology* 2018;105:4-9.
150. Liu J, Ding Y, Liu Z, Liang X. Senescence in mesenchymal stem cells: functional alterations, molecular mechanisms, and rejuvenation strategies. *Frontiers in Cell and Developmental Biology* 2020;8:258.
151. Sanna A, Firinu D, Zavattari P, Valera P. Zinc status and autoimmunity: a systematic review and meta-analysis. *Nutrients* 2018;10:68.

152. Lei L, Su J, Chen J, Chen W, Chen X, Peng C. Abnormal serum copper and zinc levels in patients with psoriasis: A meta-analysis. *Indian journal of dermatology* 2019;64:224.
153. Straubel D, Thielitz A, Reinhold A, Grüngreiff K, Reinhold D. Combined treatment with zinc aspartate and intravenous immunoglobulins (IVIg) ameliorates experimental autoimmune encephalomyelitis (EAE). *Journal of Immunology Research*, 2018.
154. Rosenkranz E, Metz CH, Maywald M, et al. Zinc supplementation induces regulatory T cells by inhibition of Sirt-1 deacetylase in mixed lymphocyte cultures. *Molecular nutrition & food research* 2016;60:661-71.
155. Maywald M, Wang F, Rink L. The intracellular free zinc level is vital for treg function and a feasible tool to discriminate between treg and activated Th cells. *International Journal of Molecular Sciences*, 2018;19:3575.
156. Lai XL, Xiong WJ, Li LS, et al. Zinc deficiency compromises the maturational competence of porcine oocyte by inducing mitophagy and apoptosis. *Ecotoxicology and Environmental Safety* 2023;252:114593.
157. Hayashida K, Omagari K, Masuda JI, et al. The sperm mitochondria-specific translocator has a key role in maternal mitochondrial inheritance. *Cell Biol. Int.* 2005;29:472–81.
158. Hayashida K, Omagari K, Masuda JI, Kohno S. An integrase of endogenous retrovirus is involved in maternal mitochondrial DNA inheritance of the mouse. *Biochem. Biophys. Res. Commun.* 2008;366:206–11.
159. Hayashida K, Kohno S. Hybrid male sterility is caused by mitochondrial DNA deletion. *Mol. Biol. Rep.* 2009;36:1365-9.
160. Hayashida K. On The Origin of Speciation. *EcoEvoRxiv.org* 2022.
161. Maurizy C, Quinternet M, Abel Y, et al. The RPAP3-Cterminal domain identifies R2TP-like quaternary chaperones. *Nature Communications*, 2018;9:2093.
162. Zeng Y, Zhao K, Oros Klein K, et al. Thousands of CpGs Show DNA Methylation Differences in ACPA-Positive Individuals. *Genes* 2021;12:1349.
163. Virakul S, Somporn P, Pisitkun T, et al. Integrative analysis of proteomics and DNA methylation in orbital fibroblasts from graves' ophthalmopathy. *Frontiers in endocrinology* 2021;11:619989.
164. Zhou X, Tan FK, Xiong M, Arnett FC, Feghali-Bostwick CA. Monozygotic twins clinically discordant for scleroderma show concordance for fibroblast gene expression profiles. *Arthritis & Rheumatism: Official Journal of the American College of Rheumatology* 2005;52:3305-14.
165. Zhang HT, Mi L, Wang T, et al. PINK1/Parkin-mediated mitophagy play a protective role in manganese induced apoptosis in SH-SY5Y cells. *Toxicology In Vitro* 2016;34:212-9.
166. Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. *Journal of Cell Biology* 2013;200:373-83.
167. Chen J, Chopp M. Exosome therapy for stroke. *Stroke*, 2018;49:1083-90.
168. Liang B, Peng P, Chen S, et al. Characterization and proteomic analysis of ovarian cancer-derived exosomes. *Journal of proteomics* 2013;80:171-82.
169. Blanchard N, Lankar D, Faure F, et al. TCR activation of human T cells induces the production of exosomes bearing the TCR/CD3/ζ complex. *The Journal of Immunology* 2002;168:3235-41.
170. Rialland P, Lankar D, Raposo G, Bonnerot C, Hubert P. BCR-bound antigen is targeted to exosomes in human follicular lymphoma B-cells 1. *Biology of the Cell* 2006;98:491-501.
171. Chiu I, Davis DM, Strominger JL. Trafficking of spontaneously endocytosed MHC proteins. *Proceedings of the National Academy of Sciences* 1999;96:13944-9.
172. Banales JM, Sáez E, Úriz M, et al. Up-regulation of microRNA 506 leads to decreased Cl⁻/HCO₃⁻ anion exchanger 2 expression in biliary epithelium of patients with primary biliary cirrhosis. *Hepatology* 2012;56:687-97.
173. Graham JB, Canniff NP, Hebert DN. TPR-containing proteins control protein organization and homeostasis for the endoplasmic reticulum. *Critical reviews in biochemistry and molecular biology* 2019;54:103-18.
174. D'Andrea LD, Regan L. TPR proteins: the versatile helix. *Trends in biochemical sciences* 2003;28:655-62.
175. Chih-Hao C, Reeves WH. Recognition of multiple epitopes in the coiled-coil domain of lamin B by human autoantibodies. *Molecular immunology* 1992;29:1055-64.
176. Jabet C, Sprague ER, VanDemark AP, Wolberger C. Characterization of the N-terminal Domain of the Yeast Transcriptional Repressor Tup1: PROPOSAL FOR AN ASSOCIATION MODEL OF THE REPRESSOR COMPLEX Tup1· Ssn6. *Journal of Biological Chemistry* 2000;275:9011-8.
177. Sun L, Edelmann FT, Kaiser CJ, Papsdorf K, Gaiser AM, Richter K. The lid domain of *Caenorhabditis elegans* Hsc70 influences ATP turnover, cofactor binding and protein folding activity. *PLoS One* 2012;7:e33980.
178. Zininga T, Ramatsui L, Shonhai A. Heat shock proteins as immunomodulators. *Molecules* 2018;23:2846.

179. Dohlman JG, Lupas A, Carson M. Long charge-rich α -helices in systemic autoantigens. *Biochemical and biophysical research communications* 1993;195:686-96.
180. Krishna M, Nadler SG. Immunogenicity to biotherapeutics—the role of anti-drug immune complexes. *Frontiers in immunology* 2016;7:21.
181. Smith AJ, Bustamante-Marin XM, Yin W, et al. The role of SPAG1 in the assembly of axonemal dyneins in human airway epithelia. *Journal of Cell Science* 2022;135:jcs259512.
182. Yokoyama A, Igarashi K, Sato T, et al. Identification of myelin transcription factor 1 (MyT1) as a subunit of the neural cell type-specific lysine-specific demethylase 1 (LSD1) complex. *Journal of Biological Chemistry* 2014;289:18152-62.
183. Stebbing J, Savage P, Patterson S, Gazzard B. All for CD91 and CD91 for all. *Journal of Antimicrobial Chemotherapy* 2004;53:1-3.
184. Dorak MT, Karpuzoglu E. Gender differences in cancer susceptibility: an inadequately addressed issue. *Frontiers in genetics* 2012;3:268.
185. Fugazzola L, Cirello V, Beck-Peccoz P. Microchimerism and endocrine disorders. *The Journal of Clinical Endocrinology* 2012;97:1452-61.
186. Bonnet D, Warren EH, Greenberg PD., Dick JE, Riddell SR. CD8+ minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. *Proceedings of the National Academy of Sciences* 1999;96:8639-44.
187. Austad SN, Fischer KE. Sex differences in lifespan. *Cell metabolism* 2016;23:1022-33.
188. Song R, Ro S, Michaels JD, Park C, McCarrey JR, Yan W. Many X-linked microRNAs escape meiotic sex chromosome inactivation. *Nature genetics* 2009;41:488-93.
189. Tyndall A, Dazzi F. Chronic GVHD as an autoimmune disease. *Best Practice & Research Clinical Haematology* 2008;21:281-9.
190. Tsubota K, Fujita H, Tsuzaka K, Takeuchi T. Mikulicz's disease and Sjogren's syndrome. *Investigative ophthalmology & visual science* 2000;41:1666-73.
191. Yamamoto M, Takahashi H, Sugai S, Imai K. Clinical and pathological characteristics of Mikulicz's disease (IgG4-related plasmacytic exocrinopathy). *Autoimmunity reviews* 2005;4:195-200.
192. Stone JH, Zen Y, Deshpande V. IgG4-related disease. *New England Journal of Medicine* 2012;366:539-51.
193. Maslinska M, Dmowska-Chalaba J, Jakubaszek M. The role of IgG4 in autoimmunity and rheumatic diseases. *Frontiers in Immunology* 2022;12:787422.
194. Walter RB, Milano F, Brasky TM, White E. Long-term use of acetaminophen, aspirin, and other nonsteroidal anti-inflammatory drugs and risk of hematologic malignancies: results from the prospective Vitamins and Lifestyle (VITAL) study. *Journal of clinical oncology* 2011;29:2424.
195. De Bari C. Are mesenchymal stem cells in rheumatoid arthritis the good or bad guys?. *Arthritis research & therapy* 2015;17:1-9.
196. Smits HH, Yazdanbakhsh M. Chronic helminth infections modulate allergen-specific immune responses: protection against development of allergic disorders?. *Annals of medicine* 2007;39:428-39.
197. Kamisawa T. Epidemiology of autoimmune pancreatitis. *The Pancreas: An Integrated Textbook of Basic Science, Medicine, and Surgery* 2023;533-9.
198. Trivedi PJ, Bowlus CL, Yimam KK, Razavi H, Estes C. Epidemiology, natural history, and outcomes of primary sclerosing cholangitis: a systematic review of population-based studies. *Clinical Gastroenterology and Hepatology* 2022;20:1687-700.
199. Hennessey JV. Riedel's thyroiditis: a clinical review. *The Journal of Clinical Endocrinology & Metabolism* 2011;96:3031-41.
200. Yamamoto M, Takahashi H, Ohara M, et al. A new conceptualization for Mikulicz's disease as an IgG4-related plasmacytic disease. *Modern Rheumatology* 2006;16:335-40.
201. Quattrocchio G, Roccatello D. IgG4-related nephropathy. *Journal of Nephrology* 2016;29:487-93.
202. Mauro D, Thomas R, Guggino G, Lories R, Brown MA, Ciccio F. Ankylosing spondylitis: an autoimmune or autoinflammatory disease?. *Nature Reviews Rheumatology* 2021;17:387-404.
203. Gudjonsson JE, Elder JT. Psoriasis: epidemiology. *Clinics in dermatology* 2007;25:535-46.
204. Efthimiou P, Kontzias A, Hur P, Rodha K, Ramakrishna GS, Nakasato P. Adult-onset Still's disease in focus: Clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapies. In *Seminars in arthritis and rheumatism* WB Saunders. 2021, August;51:858-74.
205. Rakar S, Sinagra G, Di Lenarda A, et al. Epidemiology of dilated cardiomyopathy: a prospective post-mortem study of 5252 necropsies. *European heart journal* 1997;18:117-23.
206. González-Gay MA, Matteson EL, Castañeda S. Polymyalgia rheumatica. *The Lancet* 2017;390:1700-12.
207. Lai WL, Yeh TH, Chen PM, et al. Membranous nephropathy: a review on the pathogenesis, diagnosis, and treatment. *Journal of the Formosan Medical Association* 2015;114:102-11.
208. Lozada-Nur F, Miranda C. Oral lichen planus: epidemiology, clinical characteristics, and associated diseases. In *Seminars in cutaneous Medicine and Surgery* WB Saunders. 1997,

December;16:273-7.

209. Donadio JV, Grande JP. IgA nephropathy. New England Journal of Medicine 2002;347:738-48..

Supplementary information

Table S1. Natural microchimerism: Onset probability (OnP), odds and odds ratio by gender and age for each combination of effector cells/target cells. ♀→♂: female effector cells/male target cells.

| effector →target | age and gender | | | | | | | | | | | | | | | | |
|---------------------|----------------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|---|
| | 10 | | 20 | | 30 | | 40 | | 50 | | 60 | | 70 | | 80 | | |
| | F | M | F | M | F | M | F | M | F | M | F | M | F | M | F | M | |
| ♀→♂ | OnP | 0.003949 | 0.004977 | 0.002868 | 0.003233 | 0.037259 | 0.001834 | 0.025767 | 0.000779 | 0.016259 | 0.000069 | 0.009142 | 0.000029 | 0.003838 | 0.000007 | 0.000352 | 0 |
| | odds | 0.00396 | 0.00500 | 0.00288 | 0.00324 | 0.03870 | 0.00184 | 0.02645 | 0.00078 | 0.01653 | 0.00007 | 0.00923 | 0.00003 | 0.00385 | 0.00001 | 0.00035 | 0 |
| | odds ratio | 396 | 500 | 288 | 324 | 3870 | 184 | 2645 | 78 | 1653 | 7 | 923 | 3 | 385 | 1 | 35 | 0 |
| ♂→♀ | OnP | 0.000602 | 0.047699 | 0.000421 | 0.030993 | 0.007447 | 0.017584 | 0.00501 | 0.007473 | 0.003012 | 0.000659 | 0.001822 | 0.000283 | 0.000969 | 0.000063 | 0.000352 | 0 |
| | odds | 0.00060 | 0.05009 | 0.00042 | 0.03198 | 0.00750 | 0.01790 | 0.01790 | 0.00753 | 0.00302 | 0.00066 | 0.00183 | 0.00028 | 0.00097 | 0.00006 | 0.00035 | 0 |
| | odds ratio | 10 | 835 | 7 | 533 | 125 | 298 | 84 | 126 | 50 | 11 | 31 | 5 | 16 | 1 | 6 | 0 |
| ♀→♀ | OnP | 0.004551 | 0.052676 | 0.003289 | 0.034226 | 0.044706 | 0.019418 | 0.030777 | 0.008252 | 0.019271 | 0.000728 | 0.010964 | 0.000312 | 0.004807 | 0.000070 | 0.000704 | 0 |
| | odds | 0.00457 | 0.05561 | 0.0030 | 0.03544 | 0.04680 | 0.01980 | 0.03175 | 0.00832 | 0.01965 | 0.00073 | 0.01109 | 0.00031 | 0.00483 | 0.00007 | 0.00070 | 0 |
| | odds ratio | 65 | 794 | 47 | 470 | 669 | 283 | 454 | 119 | 281 | 10 | 158 | 4 | 69 | 1 | 10 | 0 |
| ♀→♂ | OnP | 0.048355 | 0.000425 | 0.034200 | 0.000272 | 0.056575 | 0.000150 | 0.033605 | 0.000059 | 0.014916 | 0 | 0.008973 | 0 | 0.003531 | 0 | 0 | 0 |
| | odds | 0.05081 | 0.00043 | 0.03541 | 0.00027 | 0.05997 | 0.00015 | 0.03477 | 0.00006 | 0.01514 | 0 | 0.00905 | 0 | 0.00354 | 0 | 0 | 0 |
| | odds ratio | 847 | 7 | 590 | 5 | 1000 | 3 | 580 | 1 | 252 | 0 | 151 | 0 | 59 | 0 | 0 | 0 |
| ♂→♂ | OnP | 0 | 0.004091 | 0 | 0.002991 | 0.000300 | 0.002063 | 0.000208 | 0.001306 | 0.000131 | 0.000722 | 0.000070 | 0.000309 | 0.000025 | 0.000069 | 0 | 0 |
| | odds | 0 | 0.00411 | 0 | 0.00300 | 0.00030 | 0.00207 | 0.00021 | 0.00131 | 0.00013 | 0.00072 | 0.00007 | 0.00031 | 0.00003 | 0.00007 | 0 | 0 |
| | odds ratio | 0 | 137 | 0 | 100 | 10 | 69 | 7 | 44 | 4 | 24 | 2 | 34 | 1 | 2 | 0 | 0 |
| all LLBMC →all Soc | OnP | 0.057192 | 0.057192 | 0.037489 | 0.037489 | 0.101581 | 0.021640 | 0.042714 | 0.009618 | 0.035725 | 0.001450 | 0.019537 | 0.000621 | 0.008363 | 0.000138 | 0.001472 | 0 |
| | odds | 0.06066 | 0.06066 | 0.03895 | 0.03895 | 0.11307 | 0.02213 | 0.04462 | 0.00971 | 0.03705 | 0.00145 | 0.01993 | 0.00062 | 0.00843 | 0.00014 | 0.00147 | 0 |
| | odds ratio | 433 | 433 | 278 | 278 | 808 | 158 | 319 | 69 | 264 | 10 | 142 | 4 | 60 | 1 | 11 | 0 |

Table S2. Natural microchimerism: Female to male ratio of onset probability odds by age for each combination of effector cells/target cells. ♀→♂: female effector cells/male target cells.

| effector →target | age | | | | | | | |
|--------------------|-------|-------|-------|-------|-------|-------|-------|----|
| | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 |
| ♀→♂ | 0.8 | 0.9 | 21.0 | 33.9 | 236.1 | 307.7 | 385.0 | - |
| ♂→♀ | 0.01 | 0.01 | 0.4 | 2.4 | 4.6 | 6.5 | 16.2 | - |
| ♀→♀ | 0.08 | 0.01 | 2.4 | 3.8 | 26.9 | 35.8 | 69.0 | - |
| ♂→♂ | 118.2 | 131.1 | 399.8 | 579.5 | - | - | - | - |
| ♀→♂ | 0 | 0 | 0.1 | 0.2 | 0.2 | 0.1 | 0.4 | - |
| all LLBMC →all Soc | 1.0 | 1.0 | 5.1 | 4.6 | 25.6 | 32.1 | 60.2 | - |

Table S3. Artificial microchimerism: Onset probability (OnP), odds and odds ratio by gender of donor and recipient for each combination of effector cells/target cells. F→M: female donor/male recipient. ♀→♂: female effector cells/male target cells.

| effector →target | | donor →recipient | | | |
|---------------------|------------|------------------|----------|----------|----------|
| | | F→M | M→F | F→F | M→M |
| ♀→♂ | OnP | 0.046047 | 0.001484 | 0.037259 | 0.001834 |
| | odds | 0.04827 | 0.00149 | 0.03870 | 0.00184 |
| | odds ratio | 32.4 | 1.0 | 26.0 | 1.2 |
| ♂→♀ | OnP | 0.001484 | 0.105109 | 0.007447 | 0.017584 |
| | odds | 0.00149 | 0.11745 | 0.00750 | 0.01790 |
| | odds ratio | 1.0 | 78.8 | 5.0 | 12.0 |
| ♀→♀ | OnP | 0.047531 | 0.106593 | 0.044706 | 0.019418 |
| | odds | 0.04990 | 0.11931 | 0.04680 | 0.01980 |
| | odds ratio | 2.5 | 6.0 | 2.4 | 1.0 |
| ♂→♂ | OnP | 0.019367 | 0.003617 | 0.098580 | 0.000467 |
| | odds | 0.01975 | 0.00363 | 0.10936 | 0.00047 |
| | odds ratio | 42.0 | 7.7 | 232.7 | 1.0 |
| ♀→♂ | OnP | 0.003467 | 0.033280 | 0.001555 | 0.041130 |
| | odds | 0.00348 | 0.03443 | 0.00156 | 0.04289 |
| | odds ratio | 2.2 | 22.1 | 1.0 | 27.5 |
| all LLBMC →all Soc | OnP | 0.070365 | 0.126615 | 0.143465 | 0.061015 |
| | odds | 0.07569 | 0.14497 | 0.16749 | 0.06498 |
| | odds ratio | 1.2 | 2.2 | 2.6 | 1.0 |

Table S4. Artificial microchimerism: Onset probability (OnP), odds and odds ratio by pregnancy history of donor and recipient for each combination of effector cells/target cells. F*: nulliparous. F***: parous. M: male. F*→M: nulliparous donor/male recipient. ♀→♂: female effector cells/male target cells.

| effector →target | | donor →recipient | | | | | | | | |
|---------------------|------------|------------------|----------|----------|----------|----------|----------|----------|----------|----------|
| | | F*→M | M→F* | F**→F* | F**→M | M→F** | F**→F** | F**→F* | M→M | |
| ♀→♂ | OnP | 0.042772 | 0.000084 | 0.001959 | 0.049322 | 0.002884 | 0.079425 | 0.067259 | 0.002259 | 0.001834 |
| | odds | 0.04468 | 0.00008 | 0.001959 | 0.05188 | 0.00289 | 0.08628 | 0.07211 | 0.00226 | 0.00184 |
| | odds ratio | 559 | 1 | 25 | 649 | 36 | 1079 | 901 | 28 | 23 |
| ♂→♀ | OnP | 0.000084 | 0.073709 | 0.000272 | 0.002884 | 0.136509 | 0.075872 | 0.000572 | 0.009322 | 0.017584 |
| | odds | 0.00008 | 0.07957 | 0.00027 | 0.00289 | 0.15809 | 0.08210 | 0.00057 | 0.00941 | 0.01790 |
| | odds ratio | 1 | 995 | 3 | 36 | 1976 | 1026 | 7 | 118 | 224 |
| ♀→♀ | OnP | 0.042856 | 0.073793 | 0.002231 | 0.052206 | 0.139393 | 0.155297 | 0.067831 | 0.011581 | 0.019418 |
| | odds | 0.04477 | 0.07967 | 0.0022 | 0.05508 | 0.16197 | 0.18385 | 0.07277 | 0.01172 | 0.01980 |
| | odds ratio | 20 | 36 | 1 | 25 | 72 | 82 | 32 | 5 | 9 |
| ♂→♂ | OnP | 0.017967 | 0.002217 | 0.060155 | 0.020767 | 0.005017 | 0.139505 | 0.105923 | 0.069202 | 0.000467 |
| | odds | 0.01830 | 0.00222 | 0.06401 | 0.02121 | 0.00504 | 0.16212 | 0.11847 | 0.07435 | 0.00047 |
| | odds ratio | 39 | 5 | 136 | 45 | 11 | 345 | 252 | 158 | 1 |
| ♀→♂ | OnP | 0.000192 | 0.001880 | 0.000005 | 0.006742 | 0.064680 | 0.005605 | 0.000305 | 0.000305 | 0.041130 |
| | odds | 0.00019 | 0.00188 | 0.00001 | 0.00679 | 0.06915 | 0.00564 | 0.00031 | 0.00031 | 0.04289 |
| | odds ratio | 19 | 188 | 1 | 679 | 6915 | 564 | 31 | 31 | 4289 |
| all LLBMC →all Soc | OnP | 0.009350 | 0.061015 | 0.061015 | 0.080036 | 0.192536 | 0.221886 | 0.192536 | 0.079715 | 0.061015 |
| | odds | 0.00944 | 0.06498 | 0.06498 | 0.08700 | 0.23845 | 0.28516 | 0.23845 | 0.08662 | 0.06498 |
| | odds ratio | 1 | 7 | 7 | 9 | 25 | 30 | 25 | 9 | 7 |

Table S5. Artificial microchimerism: Onset probability (OnP), odds and odds ratio by pregnancy history of the donor for each combination of effector cells/target cells. F*: nulliparous. F***: parous. M: male. X: all recipients (nulliparous, parous and male). F*→X: nulliparous donor/all recipients. ♀→♂: female effector cells/male target cells.

| effector →target | | donor →recipient | | |
|---------------------|------------|-------------------|-------------------|----------|
| | | F [♀] →X | F [♀] →X | M→X |
| ♀→♂ | OnP | 0.111990 | 0.131006 | 0.004802 |
| | odds | 0.12611 | 0.15076 | 0.00483 |
| | odds ratio | 26 | 31 | 1 |
| ♂→♀ | OnP | 0.000928 | 0.088078 | 0.227802 |
| | odds | 0.00093 | 0.09659 | 0.29500 |
| | odds ratio | 1 | 104 | 317 |
| ♀→♀ | OnP | 0.112918 | 0.219084 | 0.232604 |
| | odds | 0.12729 | 0.28055 | 0.30311 |
| | odds ratio | 1 | 2 | 18 |
| ♂→♂ | OnP | 0.184045 | 0.229474 | 0.007701 |
| | odds | 0.22556 | 0.29781 | 0.00776 |
| | odds ratio | 29 | 38 | 1 |
| ♀→♂ | OnP | 0.000502 | 0.012652 | 0.107690 |
| | odds | 0.00050 | 0.01281 | 0.12069 |
| | odds ratio | 1 | 31 | 24 |
| all LLBMC →all Soc | OnP | 0.192536 | 0.381637 | 0.314566 |
| | odds | 0.23845 | 0.61717 | 0.45893 |
| | odds ratio | 1 | 3 | 2 |

Abbreviations of autoimmune diseases

AA: alopecia areata
AG (PA): atrophic gastritis (pernicious anamia)
ACHA: acquired hemophilia A
AD: Addison's disease
ADEM: autoimmune disseminated encephalomyelitis
AE: autoimmune encephalitis
AIH-1: autoimmune hepatitis type 1
AIH-2: autoimmune hepatitis type 2
AIHA: autoimmune hemolytic anemia
AIP: autoimmune pancreatitis
ALPS: autoimmune lymphoproliferative syndrome
AMC: autoimmune myocarditis
AN: autoimmune neutropenia
APS: antiphospholipid syndrome
APGS-1: autoimmune polyglandular syndrome-1
APGS-2: autoimmune polyglandular syndrome-2
AS: ankylosing spondylitis
ASD: adult Still's disease
BCD: Behcet disease
BD: Batten disease
BP: bullous pemphigoid
B27: HLA-B27-associated acute anterior uveitis
CD: Crohn's disease
CIDP: chronic inflammatory demyelinating polyneuropathy
COD: coeliac disease
CP: cicatricial pemphigoid
CREST: CREST syndrome
CSS: Churg-Strauss syndrome
DCM: dilated cardiomyopathy
DH: dermatitis herpetiformis
DLE: discoid lupus erythematosus
EAE: experimental autoimmune encephalomyelitis
EBA: epidermolysis bullosa acquisita
EM: eosinophilic myocarditis
EMC: essential mixed cryoglobulinemia
FS: Felty's syndrome
GBS: Guillain-Barré syndrome
GCA (TA): giant cell arteritis (temporal arteritis)
GCM: giant cell myocarditis
GD: Graves' disease
GO: Graves' ophthalmopathy
GPD: Goodpasture's disease
HD: Hashimoto's autoimmune thyroiditis
HE: Hashimoto's encephalopathy
IgAN: IgA nephropathy
ITP: immune thrombocytopenic purpura
KD: Kawasaki disease
LE: limbic encephalitis
LM: linear morphea

MCTD: mixed connective tissue disease
MD: Mikulicz's disease
MG: myasthenia gravis
MGN: membranous glomerulonephropathy
MPA: microscopic polyangitis
MS: multiple sclerosis
NL: narcolepsy
OLP: oral lichen planus
PAN: polyarteritis nodosa
PBC: primary biliary cirrhosis
PF/PV: pemphigus foliaceus/pemphigus vulgaris
PM/DM: polymyositis/dermatomyositis
PMR: polymyalgia rheumatica
PSC: primary sclerosing cholangitis
PSV/PSP: psoriasis vulgaris/pustular psoriasis
RA: rheumatoid arthritis
RF: rheumatic fever
RP: relapsing polychondritis
RT: Riedel's thyroiditis
SSc: scleroderma
SjS: Sjogren's syndrome
SLE: systemic lupus erythematosus
SO: sympathetic ophthalmia
SD: Still's disease
TA: Takayasu arteritis
TIN: tubulointerstitial nephritis
T1D: diabetes mellitus type I
UC: ulcerative colitis
VL: vitiligo
WG: Wegener's granulomatosis